

CITATION REPORT

List of articles citing

Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck

DOI: 10.1056/nejm199009203231205

New England Journal of Medicine, 1990, 323, 795-801.

Source: <https://exaly.com/paper-pdf/21618110/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1186	Regulation of Cell Differentiation and Proliferation by Retinoids and Transforming Growth Factor ?. 1990 , 2-15		
1185	Coming of age--the chemoprevention of cancer. <i>New England Journal of Medicine</i> , 1990 , 323, 825-7	59.2	77
1184	Differential effects of all-trans and 13-cis-retinoic acid on mRNA levels of nuclear retinoic acid receptors in rat lung and liver. 1991 , 180, 1137-44		15
1183	Adjuvant chemotherapy in early breast cancer and incidence of new primary malignancies. 1991 , 338, 535-8		30
1182	Lung cancer chemoprevention: facts and hopes. 1991 , 7, 133-150		6
1181	Selenium, retinol, retinol-binding protein, and uric acid. From epidemiology to clinical prevention trials. 1991 , 1, 473-5		1
1180	The noninvasive mouse ear swelling assay. I. Refinements for detecting weak contact sensitizers. 1991 , 17, 790-806		48
1179	Nuclear receptors for retinoids: mediators of retinoid effects on normal and malignant cells. 1991 , 45, 145-56		51
1178	Carotenoids enhance gap junctional communication and inhibit lipid peroxidation in C3H/10T1/2 cells: relationship to their cancer chemopreventive action. 1991 , 12, 2109-14		445
1177	BOMM: new solution or old problem?. 1991 , 9, 605-6		
1176	Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). <i>New England Journal of Medicine</i> , 1991 , 324, 1385-93	59.2	1073
1175	6'-substituted naphthalene-2-carboxylic acid analogs, a new class of retinoic acid receptor subtype-specific ligands. 1991 , 179, 1554-61		65
1174	Accidental astemizole overdose in young children. 1991 , 338, 538-40		70
1173	Multiple cancers of the upper aero-digestive tract: the challenge of risk factor identification. 1991 , 60, 1-8		14
1172	Canthaxanthin and excess vitamin A alter alpha-tocopherol, carotenoid and iron status in adult rats. 1991 , 121, 1649-55		21
1171	Isotretinoin for prevention of second primary squamous cell carcinoma of the head and neck. 1991 , 105, 752-4		5
1170	Chemoprevention in Head and Neck Cancer. 1991 , 5, 783-795		10

1169	Second malignant tumours in head and neck cancer. 1991 , 302, 193-4		28
1168	Retinoic acid affects the expression of nuclear retinoic acid receptors in tissues of retinol-deficient rats. 1991 , 88, 8272-6		98
1167	The EUROSCAN Study. EUROSCAN Steering Committee. 1991 , 64, 985-9		58
1166	Ultraviolet radiation in skin ageing and carcinogenesis: the role of retinoids for treatment and prevention. 1991 , 23, 497-505		15
1165	A road less travelled: Normal phase microbore liquid chromatography-mass spectrometry using direct liquid introduction. 1991 , 10, 177-184		8
1164	Effects of aging on beta-carotene and vitamin A status. 1991 , 14, 13-16		2
1163	Recommendations for isotretinoin use in women of childbearing potential. 1991 , 44, 1-6		35
1162	Free radicals in chemical carcinogenesis. 1991 , 69, 1123-34		47
1161	Dietary retinol: prevention or promotion of carcinogenesis in humans?. 1991 , 2, 443-50		47
1160	Oncology. 1991 , 265, 3141		3
1159	The Noninvasive Mouse Ear Swelling Assay. 1991 , 17, 790-806		1
1158	Long-time survival of a patient with glioblastoma and Turcot's syndrome. Case report. 1991 , 74, 813-5		33
1157	Beta carotene to prevent skin cancer. <i>New England Journal of Medicine</i> , 1991 , 324, 923-5	59.2	5
1156	Treatment of advanced laryngeal carcinoma. <i>New England Journal of Medicine</i> , 1991 , 325, 1656-7	59.2	1
1155	Interactions of retinoids and transforming growth factor-beta in regulation of cell differentiation and proliferation. 1991 , 5, 3-7		108
1154	Present and past smoking history and other predisposing factors in 100 lung cancer patients. 1992 , 101, 19-25		24
1153	The maturation of differentiation therapy. <i>New England Journal of Medicine</i> , 1992 , 327, 422-4	59.2	9
1152	Chemotherapy of lung cancer. <i>New England Journal of Medicine</i> , 1992 , 327, 1434-41	59.2	323

1151	Retinoids selective for retinoid X receptor response pathways. 1992 , 258, 1944-6		310
1150	Isotretinoin Does Not Prevent Basal Cell Carcinoma. 1992 , 128, 975		4
1149	Recent Developments in the Treatment of Lung Cancer. 1992 , 267, 1661		9
1148	Physiological and clinical aspects of vitamin A and its metabolites. 1992 , 29, 185-215		31
1147	Retinoids in cancer prevention and therapy. 1992 , 3, 513-26		158
1146	Retinoids--"differentiation agents" for cancer treatment and prevention. 1992 , 304, 202-13		20
1145	A quantitatively scored cancer-risk assessment tool: its development and use. 1992 , 7, 15-36		9
1144	Dobles neoplasias de pulm3n y laringe. 1992 , 28, 341-347		2
1143	Multiple members of the retinoic acid receptor family are capable of mediating the granulocytic differentiation of HL-60 cells. <i>Molecular and Cellular Biology</i> , 1992 , 12, 3743-9	4.8	84
1142	Retinoids in cancer treatment. 1992 , 32, 868-88		55
1141	Retinoid therapy for aging skin and acne. 1992 , 92, 191-6, 199-200		4
1140	Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results. 1992 , 28B, 97-102		79
1139	Oral retinoids. What should the prescriber know about their teratogenic hazards among women of child-bearing potential?. 1992 , 7, 79-85		10
1138	Protein kinase C activity during sphinganine potentiation of retinoic acid-induced differentiation in a human leukemia cell line (HL-60). 1992 , 51, 415-22		6
1137	Cancer screening and prevention: organ vs non-organ specific?. 1992 , 339, 902-3		4
1136	Vitamin A related compounds in the chemoprevention of potentially malignant oral lesions and carcinoma. 1992 , 28B, 87-9		15
1135	Orderly bone transport. 1992 , 339, 903-904		0
1134	Chemoprevention in the management of oral cancer: EUROSCAN and other studies. 1992 , 28B, 153-7		13

1133	Retinoids for the future: oncology. 1992 , 27, S34-7	14
1132	Potential role of beta-carotene and antioxidant vitamins in the prevention of oral cancer. 1992 , 669, 260-7; discussion 267-8	13
1131	All-trans-retinoic acid: what is it good for?. 1992 , 10, 1659-61	8
1130	Retinoids in cancer therapy. 1992 , 10, 839-64	433
1129	Neoadjuvant chemotherapy in head and neck cancer: no way to preserve a larynx. 1992 , 10, 343-5	16
1128	The incidence of second primary tumors in long-term survivors of small-cell lung cancer. 1992 , 10, 1519-24	73
1127	Physical Anthropology. 1992 , 24, 601-702	
1126	Assessing quality of life in head and neck cancer. 1992 , 1, 5-17	116
1125	Gap-junctional protein connexin 43 is expressed in dermis and epidermis of human skin: differential modulation by retinoids. 1992 , 99, 460-7	61
1124	Modulation of growth in normal and malignant melanocytic cells by all-trans retinoic acid. 1992 , 19, 27-33	20
1123	Retinoids and photodamage. 1992 , 127 Suppl 41, 14-20	16
1122	The effect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial. 1992 , 65, 737-43	75
1121	Adjuvant chemotherapy for resectable squamous cell carcinoma of the head and neck. Report on Intergroup Study 0034. 1992 , 23, 885-6	11
1120	Vitamin neurotoxicity. 1992 , 6, 41-73	71
1119	Prevention of second head and neck cancers. 1992 , 2, 206-212	10
1118	Chemoprevention clinical trials. 1992 , 267, 291-5	31
1117	The effects of microtubule disrupting drugs on the differentiation of HL-60 leukemia cells. 1992 , 16, 929-35	14
1116	Intermediate biomarkers of precancer and their application in chemoprevention. 1992 , 16G, 15-21	20

1115	Intermediate biomarkers in upper aerodigestive tract and lung chemoprevention trials. 1992 , 16G, 33-8	15
1114	Candidate biomarkers for application as intermediate end points of lung carcinogenesis. 1992 , 16G, 183-6	3
1113	The effect of retinoic acid on chemosensitivity of PA-1 human teratocarcinoma cells and its modulation by an activated N-ras oncogene. 1992 , 51, 646-51	17
1112	Scientific basis for cancer prevention. Intermediate cancer markers. 1993 , 72, 978-83	14
1111	Chemoprevention. Strategies for the control of cancer. 1993 , 72, 984-90	35
1110	Genetic susceptibility to cancer. 1993 , 72, 991-5	44
1109	Cancer chemoprevention. 1993 , 72, 3374-80	3
1108	Development of chemopreventive agents for lung and upper aerodigestive tract cancers. 1993 , 17F, 2-17	13
1107	Chemoprevention strategies: the relevance of premalignant and malignant lesions of the upper aerodigestive tract. 1993 , 17F, 18-26	5
1106	Papillomaviruses in head and neck disease: pathophysiology and possible regulation. 1993 , 17F, 155-64	10
1105	TGF-alpha and EGFR in head and neck cancer. 1993 , 17F, 188-91	82
1104	Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. 1993 , 17F, 255-61	54
1103	N-acetyl-l-cysteine. 1993 , 17F, 270-7	207
1102	Squamous cell carcinoma of the hypopharynx--analysis of treatment results. <i>Head and Neck</i> , 1993 , 15, 405-12	4.2 66
1101	The past, the present, the future. 1993 , 71, 1396-9	2
1100	Cancer in the elderly. 1993 , 17, 145-218	12
1099	Small cell lung cancer: etiology, biology, clinical features, staging, and treatment. 1993 , 17, 69-141	57
1098	New approaches to cell kinetics in human tumors. 1993 , 17, 327-62	2

1097	Phase II trial of 13-cis-retinoic acid plus interferon-alpha in recurrent head and neck cancer. 1993 , 11, 57-60	23
1096	Retinoic acid receptors in retinoid responsive ovarian cancer cell lines detected by polymerase chain reaction following reverse transcription. 1993 , 68, 530-6	20
1095	Fanconi's anaemia associated with multicentric Bowen's disease and decreased NK cytotoxicity. 1993 , 129, 615-8	17
1094	Cooperation between retinoic acid and phorbol esters enhances human teratocarcinoma differentiation. 1993 , 54, 115-22	11
1093	9-cis and all-trans retinoic acid induce a similar phenotype in human teratocarcinoma cells. 1993 , 54, 123-9	14
1092	Cooperation between retinoic acid and phorbol esters enhances human teratocarcinoma differentiation. 1993 , 54, 115-122	15
1091	9-cis and all-trans retinoic acid induce a similar phenotype in human teratocarcinoma cells. 1993 , 54, 123-129	17
1090	In vivo biological activity of retinoids partially correlates to their affinity to recombinant retinoic-acid receptor alpha and recombinant-cellular retinoic-acid-binding protein I. 1993 , 212, 13-26	11
1089	Tissue levels of retinoids in human embryos/fetuses. 1993 , 7, 11-5	18
1088	Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. 1993 , 85, 1483-92	1391
1087	Retinoids and tamoxifen in breast cancer chemoprevention. 1993 , 23, 53-5	8
1086	13-cis-retinoic acid and hepatic steatosis in rats. 1993 , 46, 319-25	9
1085	The EUROSCAN study: a progress report. 1993 , 14, 62-6	9
1084	Nuclear receptor/AP-1 interaction. 1993 , 14, 651-8	309
1083	Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. <i>New England Journal of Medicine</i> , 1993 , 328, 159-63	59.2 453
1082	A comparative overview of non-small cell lung cancer: 1980 versus 1991. 1993 , 9, 15-24	1
1081	Lung cancer: prevention and detection update. 1993 , 9, 174-9	
1080	Head and neck cancer. <i>New England Journal of Medicine</i> , 1993 , 328, 184-94	59.2 1412

1079	Minimising the risks of PUVA treatment. 1993 , 8, 340-9	12
1078	The value of twice yearly bronchoscopy in the work-up and follow-up of patients with laryngeal cancer. 1993 , 29A, 1096-9	20
1077	Anticlastogenic effects of 13-cis-retinoic acid in vitro. 1992 , 29A, 137-40	10
1076	Breast cancer chemoprevention. 1993 , 29A, 589-92	38
1075	The role of retinoids in preventing second lung cancers. 1993 , 9, 343-349	3
1074	EUROSCAN: the European Organization for Research and Treatment of Cancer (EORTC): Chemoprevention study in lung cancer. 1993 , 9, 351-356	18
1073	Oral cancer inhibition by micronutrients. The experimental basis for clinical trials. 1993 , 29B, 9-16	41
1072	Embryotoxicity of human sera from patients treated with isotretinoin. 1993 , 7, 809-15	4
1071	Genetic Alterations in Carcinogenesis and Chemoprevention. 1993 , 101, 253	
1070	Strategies for lung cancer chemoprevention. 1993 , 9, 357-360	1
1069	Preoperative chemotherapy for locally advanced non-small cell lung cancer. 1993 , 9, 31-37	3
1068	Biomarkers in aerodigestive tract chemoprevention trials. 1993 , 9, 361-367	1
1067	Head and neck cancer prevention: the new challenge. 1993 , 9, 169-73	2
1066	Future directions in the management of non-small cell lung cancer. 1993 , 9, 91-107	10
1065	Schizophrenia and the gut, again. 1993 , 342, 1128-9	
1064	Oral cancer: necessity for prevention strategies. 1993 , 342, 1129	31
1063	Chemoprevention of cancer. 1993 , 342, 1211-3	69
1062	Cancer prevention by carotenoids. Mechanistic studies in cultured cells. 1993 , 691, 177-91	25

1043	Anti-proliferative effects of the arotinoid Ro 40-8757 on human cancer cell lines in vitro. 1993 , 67, 1293-8		23
1042	Formation of retinoid X receptor homodimers leads to repression of T3 response: hormonal cross talk by ligand-induced squelching. <i>Molecular and Cellular Biology</i> , 1993 , 13, 7698-707	4.8	100
1041	Loss of retinoic acid receptor gamma function in F9 cells by gene disruption results in aberrant Hoxa-1 expression and differentiation upon retinoic acid treatment. 1993 , 90, 9601-5		130
1040	Biological basis for cancer treatment. 1993 , 118, 633-7		12
1039	Genetic alterations in carcinogenesis and chemoprevention. 1993 , 101 Suppl 3, 253-6		4
1038	Adjuvant treatment of stage I lung cancer with high-dose vitamin A. 1993 , 11, 1216-22		291
1037	Hyperplasia and tumours in lung, breast and other tissues in mice carrying a RAR beta 4-like transgene.. <i>EMBO Journal</i> , 1994 , 13, 5570-5580	13	39
1036	Management of head and neck cancer. 1994 , 5, 553-8		12
1035	Strategies for Chemoprotection against Aflatoxin-Induced Liver Cancer. 1994 , 281-306		8
1034	Isotretinoin therapy for recurrent respiratory papillomatosis. 1994 , 120, 405-9		24
1033	Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. 1994 , 86, 140-1		165
1032	A COMMON PATHWAY FOR THE DESTRUCTION OF CANCER-CELLS - EXPERIMENTAL-EVIDENCE AND CLINICAL IMPLICATIONS. 1994 , 4, 215		1
1031	Dietary factors and second primary cancers: a follow-up of oral and pharyngeal cancer patients. 1994 , 21, 223-32		44
1030	Timing of radiotherapy in small cell lung cancer. 1994 , 28, 543-5		1
1029	Biology and chemoprevention of head and neck cancer. 1994 , 18, 81-140		11
1028	Reaching toward and beyond the year 2000 goals for cigarette smoking. Research and public health priorities. 1994 , 74, 1423-32		15
1027	Synchronous and metachronous head and neck carcinomas. 1994 , 74, 1933-8		313
1026	Special aspects of cancer prevention trials. 1994 , 74, 2683-6		7

1025	Epidemiology, biology, and chemoprevention of aerodigestive cancer. 1994 , 74, 2719-25	18
1024	Risk of multiple primary tumors following oral squamous-cell carcinoma. 1994 , 56, 320-3	36
1023	Response of four human ovarian carcinoma cell lines to all-trans retinoic acid: relationship with induction of differentiation and retinoic acid receptor expression. 1994 , 56, 743-8	41
1022	Micronuclei, a biomarker for chemoprevention trials: results of a randomized study in oral pre-malignancy. 1994 , 59, 457-9	31
1021	Chemoprevention of cancer. 1994 , 18, 6-79	37
1020	Induction of differentiation in the cultured F9 teratocarcinoma stem cells by triterpene acids. 1994 , 120, 513-8	72
1019	Topoisomerase inhibitors potentiate the effect of retinoic acid on cell growth inhibition and induction of differentiation of leukemia HL-60 cells. 1994 , 18, 299-304	13
1018	Epidermal differentiation enhances CRABP II expression in human skin. 1994 , 103, 785-90	16
1017	A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. 1994 , 372, 107-11	300
1016	Retinoid lung cancer prevention. 1994 , 11 Suppl 3, S71-8	
1015	Chemoprevention of second primary tumours: a model for intervention trials. 1994 , 30A, 727-9	6
1014	In vivo modulation of several anticancer agents by beta-carotene. 1994 , 34, 235-41	33
1013	Chemoprevention of second primary tumours in head and neck cancer in Europe: EUROSCAN. 1994 , 30B, 367-8	15
1012	Second cancers following oral and pharyngeal cancer: patients' characteristics and survival patterns. 1994 , 30B, 381-6	36
1011	Retinoid chemoprevention of lung cancer. 1994 , 11, 92-93	
1010	Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance. 1994 , 10 Suppl 1, S73-81	2
1009	The problem of second cancers and the European experience with chemoprevention. 1994 , 11 Suppl 3, S67-70	2
1008	Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study. 1994 , 30A, 767-72	101

1007	Potential of retinoids in cancer prevention. 1994 , 20, 1-10	16
1006	Liposome-associated retinoids: production, characterization and antiproliferative activity on neoplastic cells. 1994 , 2, 281-291	12
1005	Gene therapy--its potential in the management of oral cancer. 1994 , 30B, 143-54	13
1004	The quandary of cancer prevention. 1994 , 47, 575-81	8
1003	Nuclear retinoid receptors and their mechanism of action. 1994 , 49, 327-82	48
1002	CANCER CHEMOPREVENTION BY NATURAL-PRODUCTS (REVIEW). 1994 , 1, 1139	7
1001	Cancer chemoprevention. 1994 , 12, 851-73	259
1000	Retinoids in the management of head and neck cancer. An update. 1994 , 6, 127-38	11
999	Megadose vitamins in bladder cancer: a double-blind clinical trial. 1994 , 151, 21-6	135
998	Future directions in clinical research for lung cancer. 1994 , 106, 399S-407S	10
997	Recurrences and second primary tumours in the head and neck region: differentiation by p53 mutation analysis. 1995 , 6, 933-9	17
996	p53: DNA damage, DNA repair, and apoptosis. 1996 , 127, 65-95	36
995	Second primary tumors in patients with head and neck squamous cell carcinoma. 1995 , 75, 1343-53	272
994	Chemoprevention of lung cancer. 1995 , 107, 316S-321S	12
993	Antioxidants in oral cancer prevention. 1995 , 62, 1410S-1416S	36
992	Diet and nutrition in the etiology of oral cancer. 1995 , 61, 437S-445S	69
991	Chapter 13. Retinoids for the Treatment of Oncological Disease. 1995 , 30, 119-128	6
990	4-Hydroxyphenylretinamide in the chemoprevention of cancer. 1995 , 33, 315-47	15

989	Glial Differentiation. 1995 , 36, 1777-22		4
988	Glial differentiation: a review with implications for new directions in neuro-oncology. 1995 , 36, 1-21; discussion 21-2		46
987	Targeted disruption of retinoic acid receptor alpha (RAR alpha) and RAR gamma results in receptor-specific alterations in retinoic acid-mediated differentiation and retinoic acid metabolism. <i>Molecular and Cellular Biology</i> , 1995 , 15, 843-51	4.8	143
986	all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial. 1995 , 76, 680-6		29
985	Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: a rationale for combination therapy with chemotherapeutic agents. 1995 , 61, 409-15		45
984	Evidence of a chromatin basis for increased mutagen sensitivity associated with multiple primary malignancies of the head and neck. 1995 , 61, 738-43		34
983	Retinoids and chemoprevention: clinical and basic studies. 1995 , 22, 1-10		60
982	N-acetylcysteine (NAC) and glutathione (GSH): antioxidant and chemopreventive properties, with special reference to lung cancer. 1995 , 22, 24-32		81
981	Fostering chemopreventive agent development: how to proceed?. 1995 , 22, 254-9		8
980	Seminoma and squamous cell carcinomas in association with lymphopenia. 1995 , 7, 46-7		
979	Announcements. 1995 , 7, 47		
978	Angiogenesis and cancer metastases: therapeutic approaches. 1995 , 20, 9-39		30
977	Radiation oncologists can assist head and neck cancer patients with smoking cessation. 1995 , 31, 645-9		8
976	Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial. 1995 , 19, 605-12		22
975	Intraoral Reconstructive Techniques. 1995 , 22, 91-108		10
974	Screening, Early Detection, and Early Intervention Strategies for Lung Cancer. 1995 , 2, 493-502		4
973	RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation.. <i>EMBO Journal</i> , 1995 , 14, 1187-1197	13	184
972	Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. 1995 , 13, 1950-7		134

971	The eligibility of women for clinical research trials. 1995 , 13, 293-9	5
970	Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. 1995 , 13, 1933-8	308
969	Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adults with solid tumors. 1995 , 13, 1501-8	25
968	Krebs und Ernährung: Eine kritische Betrachtung gebräuchlicher Laienliteratur. 1995 , 2, 145-160	1
967	Diet, Aging, and Cancer. 1995 , 11, 577-590	28
966	Update on Vitamins Vitamin A and Beta Carotene. 1995 , 1, 67-75	
965	Co-carcinogenesis and field cancerization: oral lesions offer first signs. 1995 , 126, 47-51	9
964	Liarozole potentiates the cancer chemopreventive activity of and the up-regulation of gap junctional communication and connexin43 expression by retinoic acid and beta-carotene in 10T1/2 cells. 1995 , 16, 2215-22	43
963	Second primary malignancies in the head and neck cancer patient. 1995 , 104, 946-54	112
962	Role of genetic factors in the etiology of squamous cell carcinoma of the head and neck. 1995 , 121, 157-60	118
961	Emerging role of beta-carotene and antioxidant nutrients in prevention of oral cancer. 1995 , 121, 141-4	31
960	Mechanisms of Toxicity and Carcinogenesis. 1995 , 23, 775-827	
959	Chemoprevention of oral carcinogenesis. 1995 , 31B, 3-15	57
958	Oral precancer: preventive and medical approaches to management. 1995 , 31B, 16-26	49
957	European School of Oncology Advisory report to the European Commission for the Europe Against Cancer Programme: oral carcinogenesis in Europe. 1995 , 31B, 75-85	34
956	Surgical treatment of stage I and II oral squamous cell carcinomas: analysis of causes of failure. 1995 , 33, 304-8	26
955	c-fos is required for malignant progression of skin tumors. 1995 , 82, 721-32	313
954	Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide. 1995 , 768, 148-62	26

953	Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. <i>New England Journal of Medicine</i> , 1995 , 332, 1405-10	59.2	339
952	Risks and benefits of retinoids in the chemoprevention of cancer. 1995 , 13, 245-56		15
951	Relation between age and head and neck cancer recurrence after surgery: a multivariate analysis. 1995 , 113, 197-203		21
950	New chemotherapy agents in the treatment of advanced non-small cell lung cancer: an update including data from the Seventh World Conference on Lung Cancer. 1995 , 12 Suppl 2, S63-99		16
949	Prévention des seconds cancers primaires par supplémentation vitaminique chez les patients traités pour un cancer ORL. 1996 , 83, 12-16		4
948	Incidence et facteurs de risque de seconds cancers primaires chez les patients traités pour un premier cancer du pharynx. 1996 , 83, 8-11		1
947	Mutagen sensitivity: enhanced risk assessment of squamous cell carcinoma. 1996 , 32B, 367-72		8
946	Current status of retinoids in chemoprevention of oral squamous cell carcinoma: an overview. 1996 , 24, 339-45		6
945	Combined effects of 13-cis-retinoic acid, tamoxifen and interferon on the growth of human breast cancer cells. 1996 , 100, 181-9		9
944	Antitumour activity of protein A in a mouse skin model of two-stage carcinogenesis. 1996 , 103, 41-7		17
943	Native cellular fluorescence identifies terminal squamous differentiation of normal oral epithelial cells in culture: a potential chemoprevention biomarker. 1996 , 104, 171-81		15
942	Apoptosis induced by retinoic acid in Hep 3B cells in vitro. 1996 , 107, 149-59		34
941	Prevention of second primary tumours with a second generation retinoid in squamous cell carcinoma of oral cavity and oropharynx: long term follow-up. 1996 , 32A, 375-6		4
940	Hexamethylene bisacetamide as a chemopreventive agent in hamster cheek pouch tumorigenesis. 1996 , 32B, 246-50		2
939	Increased radiosensitivity by a combination of 9-cis-retinoic acid and interferon- γ in breast cancer cells. 1996 , 61, 387-94		13
938	Differentiation of pancreatic carcinoma induced by retinoic acid or sodium butyrate: a morphological and molecular analysis of four cell lines. 1996 , 429, 59-68		22
937	Four synchronous malignancies of the upper aerodigestive tract--management of an unusual case. 1996 , 17, 207-9		16
936	Use of antioxidant supplements in the treatment of human oral leukoplakia. 1996 , 81, 5-14		39

935	Retinoid actions and implications for prevention and therapy of oral cancer. 1996 , 25, 69-73		12
934	Chemoprevention of colorectal cancer. 1996 , 25, 821-58		14
933	The receptor-DNA complex determines the retinoid response: a mechanism for the diversification of the ligand signal. <i>Molecular and Cellular Biology</i> , 1996 , 16, 4137-46	4.8	46
932	Benefits of neoadjuvant chemotherapy in NSCLC. 1996 , 109, 96S-101S		15
931	Differentiation therapy of acute promyelocytic leukemia: clinical and molecular features. 1996 , 14, 142-50		11
930	Antiproliferative effects of the arotinoid Ro 40-8757 in human gastrointestinal and pancreatic cancer cell lines: combinations with 5-fluorouracil and interferon-alpha. 1996 , 74, 394-9		12
929	Oxidative damage and defense. 1996 , 63, 985S-990S		241
928	Retinoid receptors in human lung cancer and breast cancer. 1996 , 350, 267-77		53
927	The efficacy of 9-cis retinoic acid in experimental models of cancer. 1996 , 38, 85-96		54
926	Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation. 1996 , 39, 34-41		48
925	Differential effects of retinoic acid and N-(4-hydroxyphenyl)retinamide on head and neck squamous cell carcinoma cells. 1996 , 106, 1471-5		15
924	Primary oral squamous cell carcinoma: A review of 92 cases. 1996 , 54, 955		3
923	New agents for cancer chemoprevention. 1996 , 26, 1-28		43
922	Strategy and planning for chemopreventive drug development: clinical development plans II. 1996 , 26, 54-71		114
921	Clinical development plan: 13-cis-Retinoic acid. 1996 , 63, 168-201		
920	Diet and other risk factors for cancer of the salivary glands:a population-based case-control study. 1996 , 67, 194-8		41
919	Long-term follow-up of larynx leukoplakia under treatment with retinyl palmitate. <i>Head and Neck</i> , 1996 , 18, 560-5	4.2	18
918	Risk biomarkers and current strategies for cancer chemoprevention. 1996 , 63, 1-14		124

917	Coordinate control of growth and cytokeratin 13 expression by retinoic acid. 1996 , 16, 6-11	4
916	Stage-directed treatment guidelines. 1996 , 20, 157-78	0
915	Chemoprevention of lung cancer. 1996 , 20, 266-271	
914	Enhancement of glycosylation of cellular glycoconjugates in the squamous carcinoma cell line MDA886Ln by beta-all-trans retinoic acid. 1996 , 13, 791-6	3
913	A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction). 1996 , 15, 247-72	107
912	Biological staging of head and neck cancer and its role in developing effective treatment strategies. 1996 , 15, 11-25	9
911	Cell, tissue and organ culture as in vitro models to study the biology of squamous cell carcinomas of the head and neck. 1996 , 15, 27-51	101
910	Clinical studies in head and neck cancer chemoprevention. 1996 , 15, 113-8	3
909	Nutrition and oral cancer. 1996 , 7, 101-11	70
908	Retinoids and apoptosis in cancer therapy. 1996 , 1, 11-24	6
907	Topical retinoids and cutaneous biology. 1996 , 21, 1-10	17
906	Retinoic acid normalizes the increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines. 1996 , 2, 237-40	96
905	Evolution of the Radiation Therapy Oncology Group clinical trials for head and neck cancer. 1996 , 35, 425-38	34
904	Transcriptional regulation of alpha1,3-galactosyltransferase in embryonal carcinoma cells by retinoic acid. Masking of Lewis X antigens by alpha-galactosylation. 1996 , 271, 3238-46	46
903	Prevention of second primary tumors by an acyclic retinoid, polypropenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. <i>New England Journal of Medicine</i> , 1996 , 334, 1561-7	59.2 603
902	Field cancerization: are multiple primary cancers monoclonal or polyclonal?. 1996 , 28, 183-8	31
901	Dietary retinoic acid inhibits mouse skin carcinogenesis irrespective of age at initiation. 1996 , 25, 249-57	9
900	Phase II trial of all-trans retinoic acid in metastatic non-small cell lung cancer. 1996 , 14, 415-20	19

899	An analysis of retinoic acid-induced gene expression and metabolism in AB1 embryonic stem cells. 1996 , 271, 14971-80	40
898	Inhibition of invasion in vitro and stimulation of aggregation by 13-cis retinoic acid correlates with the clustering of N-CAM in c-Ha-ras transformed glial cells. 1996 , 9, 1175-82	
897	Selective suppression of nuclear retinoic acid receptor beta gene expression in human pancreatic carcinomas. 1996 , 8, 445-51	3
896	Second malignancies. 1996 , 9, 763-76	2
895	New Directions in Lung Cancer: Chemoprevention. 1996 , 17, 323-334	1
894	The role of transforming growth factor-beta in the regulation of estrogen receptor expression in the MCF-7 breast cancer cell line. 1997 , 138, 1498-505	45
893	Malignant Metastatic Eccrine Poroma. 1997 , 23, 267-272	13
892	Autoinduction of retinoic acid metabolism to polar derivatives with decreased biological activity in retinoic acid-sensitive, but not in retinoic acid-resistant human breast cancer cells. 1997 , 272, 17921-8	48
891	Molecular epidemiology and retinoid chemoprevention of head and neck cancer. 1997 , 89, 199-211	84
890	Roles of Retinoids and Their Nuclear Receptors in the Development and Prevention of Upper Aerodigestive Tract Cancers. 1997 , 105, 985	2
889	Survival after treatment of small-cell lung cancer: an endless uphill battle. 1997 , 89, 1745-7	5
888	Phase II trial of 13-cis-retinoic acid for poor risk HIV-associated Kaposi's sarcoma. 1997 , 8, 518-21	20
887	Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up. 1997 , 89, 257-8	76
886	Prevention by retinoids of azoxymethane-induced tumors and aberrant crypt foci and their modulation of cell proliferation in the colon of rats. 1997 , 18, 2119-25	42
885	Androgen deprivation as a strategy for prostate cancer chemoprevention. 1997 , 89, 689-96	64
884	Dietary control of cancer. 1997 , 216, 211-23	21
883	N-(4-hydroxyphenyl)retinamide activation of a distinct pathway signaling apoptosis. 1997 , 89, 1179-81	11
882	Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. 1997 , 94, 5826-30	191

- 881 Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. **1997**, 94, 12070-4 158
- 880 Retinoid Receptors and Cancer. **1997**, 219-230
- 879 Retinoid metabolism and all-trans retinoic acid-induced growth inhibition in head and neck squamous cell carcinoma cell lines. **1997**, 76, 189-97 16
- 878 Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acid toxicity. **1997**, 8, 85-9 38
- 877 Retinoids for the management of dermatological complications of organ transplantation. **1997**, 8, 176-84 7
- 876 New approaches to the integrated management of early lung cancer. **1997**, 11, 235-52 8
- 875 Recent Molecular Advances in the Approach to Early Lung Cancer Detection and Intervention. **1997**, 105, 935 1
- 874 Perspectives in Cancer Chemoprevention. **1997**, 105, 945 19
- 873 Chemoprevention of respiratory tract cancer. **1997**, 11, 387-408 6
- 872 Prevention and early detection of lung cancer-clinical aspects. **1997**, 17, 163-74 12
- 871 Quintuple cancers: report of a case with triple cancers in the head and neck. **1997**, 25, 153-7 7
- 870 Recent advances in chemoprevention of cancer. **1997**, 278, 1073-7 685
- 869 Alternatives to chemotherapy and radiotherapy as adjuvant treatment for lung cancer. **1997**, 17 Suppl 1, S121-36 10
- 868 Carotenoids and retinoids: a review of research, clinical, and public health applications. **1997**, 37, 551-8 43
- 867 Inhibition of retinoic acid receptor function in normal human mammary epithelial cells results in increased cellular proliferation and inhibits the formation of a polarized epithelium in vitro. **1997**, 236, 16-28 42
- 866 Messages from completed randomized trials in head and neck cancer. **1997**, 23, 469-76 9
- 865 Molecular follow-up of a preinvasive bronchial lesion treated by 13-cis-retinoic acid. **1997**, 28, 108-10 8
- 864 Chemotherapy for disseminated actinic keratoses with 5-fluorouracil and isotretinoin. **1997**, 36, 236-8 57

863	Roles of retinoids and their nuclear receptors in the development and prevention of upper aerodigestive tract cancers. 1997 , 105 Suppl 4, 985-8	21
862	Recent molecular advances in the approach to early lung cancer detection and intervention. 1997 , 105 Suppl 4, 935-9	2
861	Chemoprevention of Bladder and Prostate Carcinoma. 1997 , 4, 136-141	1
860	The Etiology and Pathogenesis of Laryngeal Carcinoma. 1997 , 30, 1-19	55
859	Cancer in the Elderly: Epidemiologic and Clinical Implications. 1997 , 13, 1-14	40
858	The Role of Chemotherapy in the Curative Treatment of Head and Neck Cancer. 1997 , 6, 749-768	14
857	Chemoprevention in Oral Cancer. 1997 , 1, 116-122	1
856	Head and Neck Chemoprevention: Recent Advances. 1997 , 4, 128-135	4
855	Perspectives in cancer chemoprevention. 1997 , 105 Suppl 4, 945-54	48
854	Follow-up study in head and neck cancer: cure rate according to tumor location and stage. 1997 , 54, 38-42	33
853	Lung Cancer Chemoprevention and Management of Carcinoma in situ. 1997 , 29, 1-20	3
852	Lung cancer: review of the ECOG experience. Eastern Cooperative Oncology Group. 1997 , 54, 353-62	3
851	The effects of 13-cis retinoic acid on squamous cell carcinoma proliferation and adhesion to extracellular matrix proteins. 1997 , 107, 44-8	
850	Factors affecting smoking cessation in patients with head and neck cancer. 1997 , 107, 888-92	93
849	Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo. 1997 , 3, 686-90	82
848	Differentiation, differentiation/gene therapy and cancer. 1997 , 73, 51-65	40
847	Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity. 1997 , 40, 3567-83	55
846	Influence of retinoic acid on the differentiation pathway of T cells in the thymus. 1997 , 181, 153-62	13

845	Chemoprevention of aerodigestive cancer. 1997 , 16, 329-47	12
844	TAC-101, a benzoic acid derivative, inhibits liver metastasis of human gastrointestinal cancer and prolongs the life-span. 1998 , 16, 323-31	13
843	The A427 anchorage-independence assay as a screening tool to identify potential chemopreventive agents. 1997 , 19, 9-12	
842	Positive impact of retinyl palmitate in leukoplakia of the larynx. 1997 , 254 Suppl 1, S105-9	12
841	Adverse effects of highdose vitamin A during radiotherapy. 1997 , 254, 306-8	1
840	The role of vitamin A in differentiation and skin carcinogenesis. 1997 , 8, 426-437	21
839	Chemoprevention of human cancer: biology and therapy. 1997 , 25, 139-74	54
838	Reduction of heat-shock protein-70 after prolonged treatment with retinoids: biological and clinical implications. 1997 , 56, 143-50	14
837	Response of cell growth and retinoic acid receptor expression to retinoic acid in neoplastic and non-neoplastic prostate cell lines. 1997 , 30, 174-82	10
836	Effect of retinoic acid on HPV titration and colposcopic changes in Korean patients with dysplasia of the uterine cervix. 1997 , 67, 133-139	4
835	Retinoic acid abolishes the calcitonin gene-related peptide autocrine system in F9 teratocarcinoma cells. 1997 , 64, 447-457	3
834	Retinoic acid signaling cascade in differentiating murine epidermal keratinocytes: alterations in papilloma- and carcinoma-derived cell lines. 1997 , 20, 58-67	9
833	Chemoprevention: will it work?. 1997 , Suppl 10, 18-21	12
832	All-trans, 13-cis and 9-cis retinoic acids induce a fully reversible growth inhibition in HNSCC cell lines: implications for in vivo retinoic acid use. 1997 , 70, 194-200	55
831	Effect of dietary vitamin A or N-acetylcysteine on ethylnitrosourea-induced rat gliomas. 1998 , 40, 29-38	7
830	13-cis-retinoic acid or all-trans-retinoic acid plus interferon-alpha in recurrent cervical cancer: a Southwest Oncology Group phase II randomized trial. 1998 , 71, 386-90	33
829	Specific retinoid receptors cooperate to signal growth suppression and maturation of human embryonal carcinoma cells. 1998 , 16, 3471-80	33
828	Multiple primary malignant tumors in patients with head and neck cancer: results of a prospective study and future perspectives. 1998 , 108, 250-6	112

827	Oral leukoplakias show numerical chromosomal aberrations detected by fluorescence in situ hybridization. 1998 , 108, 917-22		10
826	Chemoprevention in head and neck cancer: basic science and clinical application. 1998 , 8, 292-301		6
825	European Consensus Statement on Lung Cancer: risk factors and prevention. Lung Cancer Panel. 1998 , 48, 167-76; discussion 164-6		54
824	Adjuvant therapy in head and neck cancer. 1998 , 48, 199-209		13
823	Chronic alcohol intake reduces retinoic acid concentration and enhances AP-1 (c-Jun and c-Fos) expression in rat liver. 1998 , 28, 744-50		117
822	Vitamin A and cancer prevention I: observations in workers previously exposed to asbestos at Wittenoom, Western Australia. 1998 , 75, 355-61		55
821	Green tea regulates cell cycle progression in oral leukoplakia. <i>Head and Neck</i> , 1998 , 20, 528-34	4.2	43
820	All-trans retinoic acid blocks the antiproliferative prodifferentiating actions of 1,25-dihydroxyvitamin D3 in normal human keratinocytes. 1998 , 174, 1-8		24
819	Clinical implication of screening p53 gene mutations in head and neck squamous cell carcinomas. 1998 , 124, 389-96		27
818	Kombinationstherapie des Zervixkarzinoms mit 13cis-Retinsäure bzw. Interferon- und Bestrahlung. 1998 , 4, 174-179		
817	Hyperfractionated radiotherapy and simultaneous cisplatin for stage-III and -IV carcinomas of the head and neck. Long-term results including functional outcome. 1998 , 174, 397-402		25
816	Induction of differentiation of the cultured rat mammary epithelial cells by triterpene acids. 1998 , 21, 398-405		7
815	Lung cancer: therapeutic modalities and cytoprotection. 1998 , 176, 145-64		5
814	Screening and chemoprevention. 1998 , 27, 111-5		3
813	Segregation analysis of squamous cell carcinoma of the head and neck: evidence for a major gene determining risk. 1998 , 62, 505-10		16
812	Improved survival in patients with head and neck cancer in the 1990s. 1998 , 23, 319-25		14
811	In vitro radiosensitization of human cervical carcinoma cells by combined use of 13-cis-retinoic acid and interferon-alpha2a. 1998 , 41, 869-73		8
810	Second primary tumors in laryngeal cancer: results of long-term follow-up. 1998 , 42, 557-62		51

809	Six primary squamous cell carcinomas of the head and neck. 1998 , 25, 101-4	3
808	Chemoprevention with interferon alfa and 13-cis retinoic acid in the adjunctive treatment of head and neck cancer. 1998 , 25, 413-8	7
807	Effects of trans-retinoic acid, 9-cis-retinoic acid, 1alpha,25-(dihydroxy)vitamin D3 and a novel apoptosis-inducing retinoid on breast cancer and endothelial cell growth. 1998 , 133, 1-8	19
806	Systemic treatment of neoplastic conditions with retinoids. 1998 , 39, S108-13	4
805	Fenretinide-induced apoptosis of human head and neck squamous carcinoma cell lines?????. 1998 , 118, 464-471	1
804	Phase I trial of retinoic acid and cis-platinum for advanced squamous cell cancer of the head and neck based on experimental evidence of drug synergism?????. 1998 , 118, 597-602	
803	Interventional nutrition for the cancer patient. 1998 , 13, 224-31	19
802	The induction of P450-mediated oxidation of all-trans retinoic acid by retinoids in head and neck squamous cell carcinoma cell lines. 1998 , 47, 955-8	4
801	Multiple primary cancers in esophageal squamous cell carcinoma: incidence and implications. 1998 , 65, 1529-34	102
800	Chemoprevention for lung cancer. 1998 , 21, S5-S6	
799	Medical oncology in the management of head and neck cancers. 1998 , 31, 881-905	1
798	Advances in the management of cutaneous T-cell lymphoma. 1998 , 16, 301-11	13
797	Preclinical and clinical models of lung cancer chemoprevention. 1998 , 12, 1037-53	41
796	Principles of human chemoprevention. 1998 , 12, 935-41, v	5
795	Cancer chemoprevention. A new way to treat cancer before it happens. 1998 , 25, 361-79	11
794	Effect of dietary curcumin and dibenzoylmethane on formation of 7,12-dimethylbenz[a]anthracene-induced mammary tumors and lymphomas/leukemias in Sencar mice. 1998 , 19, 1697-700	137
793	Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. 1998 , 90, 597-605	99
792	Mouse P450RAI (CYP26) expression and retinoic acid-inducible retinoic acid metabolism in F9 cells are regulated by retinoic acid receptor gamma and retinoid X receptor alpha. 1998 , 273, 2409-15	135

791	Fenretinide-induced apoptosis of human head and neck squamous carcinoma cell lines. 1998 , 118, 464-71	22
790	Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. 1998 , 90, 1212-8	108
789	Quantitation of chemopreventive synergism between (-)-epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. 1998 , 19, 419-24	179
788	Cancer chemoprevention: progress and promise. 1998 , 90, 1514-28	124
787	Molecular cloning and characterization of a novel retinoic acid-inducible gene that encodes a putative G protein-coupled receptor. 1998 , 273, 35008-15	113
786	Phase I trial of retinoic acid and cis-platinum for advanced squamous cell cancer of the head and neck based on experimental evidence of drug synergism. 1998 , 118, 597-602	4
785	Synergistic anti-tumor effect of 13-cRA and IFN-alpha/beta in mouse renal cell carcinoma. 1998 , 13, 145-9	1
784	The NGFI-B subfamily of the nuclear receptor superfamily (review). 1998 , 12, 1237-43	33
783	Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. 1998 , 95, 8806-11	694
782	Second primary cancer of the larynx in patients with lung cancer. 1998 , 112, 252-7	2
781	Chemically induced isomerization and differential uptake modulate retinoic acid disposition in HL-60 cells. 1998 , 12, 1627-33	20
780	Expression of Tissue Factor and Tissue Factor Pathway Inhibitor in situ in Laryngeal Carcinoma. 1999 , 82, 1659-1662	27
779	Placebo-controlled trial of 13-cis-retinoic acid activity on retinoic acid receptor-beta expression in a population at high risk: implications for chemoprevention of lung cancer. 1999 , 17, 3546-52	42
778	Dietary Carotenoids and their Metabolites as Potentially Useful Chemoprotective Agents against Cancer. 1999 , 203-229	15
777	Effects of long-term intake of retinol on selected clinical and laboratory indexes. 1999 , 69, 937-43	21
776	Screening for Lung Cancer. 1999 , 8, 747-774	19
775	Inheritance of pulmonary adenoma susceptibility in mice. 1999 , 35, 78-94	10
774	Reducing lung cancer risk: early detection. 1999 , 116, 493S-496S	11

773	Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. 1999 , 125, 1083-9	87
772	Ligand-activated retinoic acid receptor inhibits AP-1 transactivation by disrupting c-Jun/c-Fos dimerization. 1999 , 13, 276-85	90
771	Bone densities in patients receiving isotretinoin for cystic acne. 1999 , 135, 961-5	41
770	Antiangiogenic Agents in Cancer Therapy. 1999 ,	4
769	Re: Cancer chemoprevention: progress and promise. 1999 , 91, 563-5	5
768	Retinoids in lung cancer chemoprevention and treatment. 1999 , 10 Suppl 5, S95-102	16
767	Cyclin D1 proteolysis: a retinoid chemoprevention signal in normal, immortalized, and transformed human bronchial epithelial cells. 1999 , 91, 373-9	91
766	Progress in cancer chemoprevention. 1999 , 889, 1-13	101
765	Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer. 1999 , 889, 62-71	84
764	Subtractive cDNA cloning and characterization of genes induced by all-trans retinoic acid. 1999 , 886, 225-8	4
763	Synergistic inhibition of prostate cancer cell lines by a 19-nor hexafluoride vitamin D3 analogue and anti-activator protein 1 retinoid. 1999 , 79, 101-7	17
762	The role of genetic factors in predisposition to squamous cell cancer of the head and neck. 1999 , 79, 865-7	33
761	Retinoids: present role and future potential. 1999 , 80, 1-8	190
760	Abrasive esophageal cytology for the oncological follow-up of patients with head and neck cancer. 1999 , 109, 1703-8	9
759	Role of retinoid receptors in the prevention and treatment of breast cancer. 1999 , 4, 377-88	27
758	Minimal residual disease in head and neck cancer. 1999 , 18, 109-26	40
757	Sex hormone-induced mammary carcinogenesis in female Noble rats: expression of TGF-beta1 and its receptors, TGF-alpha, and EGF-R in mammary carcinogenesis. 1999 , 58, 227-39	11
756	Präklinische und klinische Aspekte zur Therapie des Zervixkarzinoms mit 13cis-Retinsäure, Interferonalphä und Bestrahlung. 1999 , 32, 306-311	

755	Plasma retinoid levels in head and neck cancer patients: a comparison with healthy controls and the effect of retinyl palmitate treatment. <i>Oral Oncology</i> , 1999 , 35, 40-4	4.4	3
754	Risk of second primary cancer following treatment of squamous cell carcinoma of the lower lip. <i>Oral Oncology</i> , 1999 , 35, 571-4	4.4	8
753	Preoperative concurrent chemoradiotherapy plus radical surgery for advanced squamous cell carcinoma of the oral cavity: an analysis of long-term results. <i>Oral Oncology</i> , 1999 , 35, 597-606	4.4	38
752	Phase II clinical trial of 13-cis-retinoic acid and interferon-alpha-2a in patients with advanced esophageal carcinoma. 1999 , 85, 1213-7		12
751	Transforming growth factor alpha (TGF-alpha) expression in dysplastic oral leukoplakia: modulation by 13-cis retinoic acid. <i>Head and Neck</i> , 1999 , 21, 566-73	4.2	22
750	In vitro effect on human leukemic K562 cells of co-administration of liposome-associated retinoids and cytosine arabinoside (Ara-C). 1999 , 62, 33-43		15
749	Induction of apoptosis in maxillary sinus cancer cells by 5-fluorouracil, vitamin A and radiation (FAR) therapy. 1999 , 256 Suppl 1, S64-9		3
748	Considerations for in vitro retinoid experiments: importance of protein interaction. 1999 , 1427, 265-75		27
747	Perspectives on cancer chemoprevention research and drug development. 2000 , 78, 199-334		196
746	Current options in management of head and neck cancer patients. 1999 , 83, 235-46, xi		10
745	Lung cancer screening in high-risk populations. 1999 , 1, 100-6; discussion 107		4
744	Induction of p21(CIP1/Waf1) and activation of p34(cdc2) involved in retinoic acid-induced apoptosis in human hepatoma Hep3B cells. 1999 , 248, 87-96		52
743	Cancer chemoprevention: present status, future expectations. 1999 , 34, 101-5; discussion 105-6; quiz 164		2
742	Angiogenesis in the development of head and neck cancer and its inhibition by chemopreventive agents. 1999 , 10, 153-64		27
741	Chemoprevention of prostate cancer: concepts and strategies. 1999 , 35, 342-50		84
740	Lokal fortgeschrittene Tumoren des HNO-Traktes: Moderne Therapiekonzepte. 2000 , 23, 177-182		
739	Carcinogenesis of head and neck cancer and the role of chemoprevention in its reversal. 2000 , 12, 240-5		19
738	Early detection and prevention of lung cancer. 2000 , 12, 143-8		28

737	Effects of sodium butyrate on growth, differentiation, and apoptosis in head and neck squamous carcinoma cell lines. <i>Head and Neck</i> , 2000 , 22, 247-56	4.2	10
736	Criteria for implementation of large and multiagent clinical chemoprevention trials. 2000 , 34, 115-20		6
735	Lack of correlation between expression of retinoic acid receptor-beta and loss of heterozygosity on chromosome band 3p24 in esophageal cancer. 2000 , 28, 196-202		18
734	Lung cancer chemoprevention. 2000 , 18, 100-5		22
733	Considerations in developing successful, population-based molecular screening and prevention of lung cancer. 2000 , 89, 2465-2467		10
732	Biomolecular markers as intermediate end points in chemoprevention trials of upper aerodigestive tract cancer. 2000 , 88, 852-5		17
731	Low serum retinol levels are associated with hepatocellular carcinoma in patients with chronic liver disease. 2000 , 14, 1295-301		55
730	First hints for a correlation between amplification of the Int-2 gene and infection with human papillomavirus in head and neck squamous cell carcinomas. 2000 , 29, 432-7		6
729	Prevention of lung cancer. 2000 , 33, 187-97		27
728	Lung cancer after head and neck cancer: role of chest radiography. 2000 , 110, 2033-6		20
727	Effect of phenobarbitone treatment against signal grass (<i>Brachiaria decumbens</i>) toxicity in sheep. 2000 , 160, 267-72		3
726	Pulmonary availability of isotretinoin in rats after inhalation of a powder aerosol. 2000 , 83, 935-40		7
725	Differentiating agents in pediatric malignancies: retinoids in neuroblastoma. 2000 , 2, 511-8		89
724	Advances in the development of retinoids as chemopreventive agents. 2000 , 130, 479S-482S		89
723	Cancer chemoprevention: a clinical reality. 2000 , 93, 518-20		5
722	Fenretinide therapy in prostate cancer: effects on tissue and serum retinoid concentration. 2000 , 18, 3804-8		22
721	Differential expression of nuclear retinoid receptors in normal and malignant prostates. 2000 , 18, 116-21		66
720	Reduced levels of connexin43 in cervical dysplasia: inducible expression in a cervical carcinoma cell line decreases neoplastic potential with implications for tumor progression. 2000 , 21, 1097-1109		2

719	Characterization of retinoic acid receptor-deficient keratinocytes. 2000 , 275, 16497-505	25
718	Retinoids: versatile biological response modifiers of vascular smooth muscle phenotype. 2000 , 87, 355-62	52
717	Comparative effects of all-trans beta-carotene vs. 9-cis beta-carotene on carcinogen-induced neoplastic transformation and connexin 43 expression in murine 10T1/2 cells and on the differentiation of human keratinocytes. 2000 , 37, 234-44	26
716	New therapeutic strategies for the treatment and prevention of head and neck cancer. 2000 , 9, 2855-72	7
715	The retinoids and cancer prevention mechanisms. 2000 , 5, 361-8	91
714	EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. 2000 , 92, 977-86	277
713	Studies on structure-activity relationships of retinoic acid receptor ligands by means of molecular modeling. 2000 , 59, 159-215	3
712	Chemoprevention of head and neck cancer. 2000 , 122, 728-735	1
711	Reduced levels of connexin43 in cervical dysplasia: inducible expression in a cervical carcinoma cell line decreases neoplastic potential with implications for tumor progression. 2000 , 21, 1097-1109	84
710	Apoptosis and restriction of G(1)/S cell cycle by fenretinide in Burkitt's lymphoma mutu I cell line accessed with bcl-6 down-regulation. 2000 , 276, 1295-301	5
709	Retinoic acid-induced blr1 expression promotes ERK2 activation and cell differentiation in HL-60 cells. 2000 , 254, 287-98	31
708	Expression of nm23 antimetastatic gene product in head and neck squamous cell carcinoma. 2000 , 122, 96-9	5
707	Chemoprevention of head and neck cancer. 2000 , 122, 728-35	20
706	Effect of 9-cis-retinoic acid on oral squamous cell carcinoma cell lines. 2000 , 151, 199-208	25
705	Concomitant administration of vitamin E does not change the side effects of isotretinoin as used in acne vulgaris: a randomized trial. 2000 , 43, 777-84	26
704	Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer. 2000 , 36, 694-709	48
703	Cancer population genetics and tumour prevention: an unfulfilled paradigm. 2000 , 36, 1189-92	7
702	Skin neoplasias including cutaneous lymphoma, melanoma, and others: unapproved treatments or indications. 2000 , 18, 201-10	

701	Second primary epithelial malignancy of nasopharynx and nasal cavity after successful curative radiation therapy of nasopharyngeal carcinoma. 2000 , 31, 227-32	28
700	GAP junctions during neoplastic transformation. 2000 , 221-262	12
699	[Current status and prospects of chemoprevention in oral squamous epithelial carcinomas and precancerous lesions]. 2000 , 4 Suppl 1, S160-8	0
698	Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. 2000 , 92, 69-73	40
697	Further evidence for chemopreventive potential of beta-carotene against experimental carcinogenesis: diethylnitrosamine-initiated and phenobarbital-promoted hepatocarcinogenesis is prevented more effectively by beta-carotene than by retinoic acid. 2000 , 37, 89-98	45
696	Tumores benignos y malignos de los labios. 2000 , 29, 1-15	
695	Primary cancer prevention trials. 2000 , 14, 809-30	5
694	Quimioterapia en el tratamiento de los c�nceres de las v�as aerodigestivas superiores (linfoma maligno excluido). 2000 , 29, 1-10	
693	Polyphenols and Cancer Prevention. 2001 , 177-190	1
692	Amphiregulin is a vitamin D3 target gene in squamous cell and breast carcinoma. 2001 , 281, 1051-6	17
691	Biallelic inactivation of retinoic acid receptor beta2 gene by epigenetic change in breast cancer. <i>American Journal of Pathology</i> , 2001 , 158, 299-303	5.8 49
690	Extended abstracts. 2001 , 32, 1-38	32
689	Chemoprevention of lung cancer. 2001 , 34 Suppl 3, S91-4	4
688	Moving to the routine management of pre symptomatic lung cancer. 2001 , 34 Suppl 2, S1-5	
687	Inhibition effect of new farnesol derivatives on all-trans-retinoic acid metabolism. 2001 , 50, 1356-60	4
686	Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. 2001 , 172, 111-8	270
685	Colorectal cancer chemoprevention: biochemical targets and clinical development of promising agents. 2001 , 37, 12-22	41
684	Nuclear receptors in cell life and death. 2001 , 12, 460-8	98

683	Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents. 2001 , 57, 56-63	19
682	IDENTIFICATION OF EFFECTIVE RETINOIDS FOR INHIBITING GROWTH AND INDUCING APOPTOSIS IN BLADDER CANCER CELLS. 2001 , 165, 986-992	29
681	Retinoid therapy of childhood cancer. 2001 , 15, 867-910	90
680	Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. 2001 , 19, 2626-37	104
679	Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. 2001 , 19, 3010-7	101
678	Angiogenesis in Oral Cancer. 2001 , 65, 1282-1290	37
677	Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma. 2001 , 127, 1253-9	69
676	Retinoid mechanisms and cyclins. 2001 , 3, 301-5	12
675	Differential expression of retinoic acid receptors and p53 protein in normal, premalignant, and malignant esophageal tissues. 2001 , 127, 237-42	23
674	Enhanced apoptosis and radiosensitization by combined 13-cis-retinoic acid and interferon-alpha2a; role of RAR-beta gene. 2001 , 51, 785-90	8
673	Long-term delivery of all-trans-retinoic acid using biodegradable PLLA/PEG-PLLA blended microspheres. 2001 , 215, 67-81	50
672	Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma. 2001 , 92, 519-23	19
671	Ifosfamide, cisplatin, and 13-Cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck: a phase I-II study. 2001 , 92, 814-21	27
670	Expression of retinoic acid receptor gamma correlates with retinoic acid sensitivity and metabolism in head and neck squamous cell carcinoma cell lines. 2001 , 92, 661-5	27
669	Mechanism of fenretinide (4-HPR)-induced cell death. 2001 , 6, 377-88	95
668	Squamous cell cancer of the oesophagus. 2001 , 15, 249-65	61
667	Low-dose retinoic acid enhances in vitro invasiveness of human oral squamous-cell-carcinoma cell lines. 2001 , 85, 122-8	13
666	Metabolism and growth inhibition of four retinoids in head and neck squamous normal and malignant cells. 2001 , 85, 630-5	19

665	No germline mutations in CDKN2A (p16) in patients with squamous cell cancer of the head and neck and second primary tumours. 2001 , 85, 1383-6	10
664	Cyclin proteolysis as a retinoid cancer prevention mechanism. 2001 , 952, 13-22	27
663	Differential effects of chromosome 3p deletion on the expression of the putative tumor suppressor RAR beta and on retinoid resistance in human squamous carcinoma cells. 2001 , 20, 6820-7	31
662	The promise of retinoids to fight against cancer. 2001 , 1, 181-93	649
661	Comprehensive cancer centres and the war on cancer. 2001 , 1, 240-5	9
660	Nutrition and Oral Precancerous Lesions. 2001 , 4, 94-102	
659	Genetic mechanisms in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2001 , 37, 115-26 4.4	53
658	Lung epithelial proliferation: a biomarker for chemoprevention trials?. 2001 , 93, 1042-3	12
657	Lower use of dental services among long term cigarette smokers. 2001 , 55, 389-93	35
656	Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. 2001 , 93, 605-18	267
655	Action of low calcemic 1alpha,25-dihydroxyvitamin D3 analogue EB1089 in head and neck squamous cell carcinoma. 2001 , 93, 745-53	61
654	Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways. 2001 , 22, 1747-55	56
653	Familiar drugs may prevent cancer. 2001 , 77, 492-7	3
652	Autonomous retinoid death signaling is suppressed by converging signaling pathways in immature leukemia cells. 2001 , 15, 1154-69	44
651	Can cure be achieved in patients with head and neck carcinomas? The problem of second neoplasm. 2001 , 1, 125-33	20
650	Regulation of gene Expression by 1alpha,25-dihydroxyvitamin D3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma Cells. 2001 , 15, 1127-39	117
649	Chemoprevention of aerodigestive tract cancers. 2002 , 53, 223-43	35
648	Metachronous second primary cancers after successful partial laryngectomy for invasive squamous cell carcinoma of the true vocal cord. 2002 , 111, 204-9	20

647	Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer. 2002 , 20, 3522-32	32
646	Expression of retinoid-related genes in serum-free cultures of normal, immortalized and malignant human oral keratinocytes. 2002 , 20, 897	
645	Preventive efficacy of receptor class selective retinoids on HER-2/neu oncogene expressing preneoplastic human mammary epithelial cells. 2002 , 21, 127	2
644	Rapid in vivo assay for topical oral cancer chemopreventive agents. 2002 , 21, 159	
643	Measurement and analysis of the chemotherapy-induced genetic instability in pediatric cancer patients. 2002 , 17, 171-5	10
642	Second Primary Tumors in Head and Neck Cancer Patients. 2002 , 122, 765-778	61
641	Apoptosis of squamous cells at different stages of carcinogenesis following 4-HPR treatment. 2002 , 23, 447-56	14
640	Second Primary Tumors in Head and Neck Cancer Patients. 2002 , 122, 765-778	18
639	Chemoprevention, Pharmacology of. 2002 , 449-455	6
638	Chemoprevention Trials. 2002 , 457-472	
637	Lung cancer. 2: screening and early diagnosis of lung cancer. 2002 , 57, 1071-8	15
636	Redevelopment of small cell lung cancer after a long disease-free period: a case report. 2002 , 32, 30-2	9
635	Lung cancer. 1: prevention of lung cancer. 2002 , 57, 994-9	18
634	Chemoprevention of head and neck cancer: an update. 2002 , 14, 318-22	5
633	Chemoprevention strategies for non-small cell lung cancer. 2002 , 14, 185-90	6
632	Second malignancies in early stage laryngeal carcinoma patients treated with radiotherapy. 2002 , 116, 190-3	35
631	Chemoprevention. 2002 , 374-388	1
630	Multiple head and neck tumors frequently originate from a single preneoplastic lesion. <i>American Journal of Pathology</i> , 2002 , 161, 1051-60	5.8 157

629	Potential of interferon-alpha in solid tumours: part 2. 2002 , 16, 349-72		26
628	Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. 2002 , 3, 593-603		207
627	Serum retinol and risk of hepatocellular carcinoma in patients with child-Pugh class A cirrhosis. 2002 , 178, 123-9		31
626	Lung cancer evolution to preinvasive management. 2002 , 23, 37-48		19
625	Lycopene inhibits proliferation and enhances gap-junction communication of KB-1 human oral tumor cells. 2002 , 132, 3754-9		119
624	Retinoic acid receptors and cancer. 2002 , 132, 3809S-3813S		22
623	Isotretinoin does not prevent second primary tumor development in people with stage I non-small-cell lung cancer. 2002 , 3, 81-83		
622	Transforming growth factor-alpha: a surrogate endpoint biomarker?. 2002 , 195, 149-58		9
621	Anticancer activity and mechanism of action of retinoids in oral and pharyngeal cancer. <i>Oral Oncology</i> , 2002 , 38, 532-42	4.4	16
620	Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. <i>Head and Neck</i> , 2002 , 24, 198-206	4.2	208
619	The effects of exogenous p53 overexpression on HPV-immortalized and carcinogen transformed oral keratinocytes. 2002 , 94, 159-66		13
618	The effect of retinoids on premalignant oral lesions: focus on topical therapy. 2002 , 95, 1258-64		39
617	Chemoprevention of lung cancer. 2002 , 4, 341-6		6
616	New approaches to lung cancer prevention. 2002 , 4, 487-94		15
615	The retinoic acid receptor-beta (RAR-beta) mRNA expression in the oral squamous cell carcinoma associated with betel quid use. 2002 , 31, 220-6		16
614	Retinoids and their receptors in cancer development and chemoprevention. 2002 , 41, 41-55		260
613	Alpha-interferon 2a and 13-cis-retinoic acid for the treatment of metastatic renal cell carcinoma. 2002 , 32, 158-62		4
612	Synchronous triple cancers at middle and lower esophagus and stomach with different histological features and genetic alterations. 2002 , 17, 724-7		3

611	Retinoic acid modulates the radiosensitivity of head-and-neck squamous carcinoma cells grown in collagen gel. 2002 , 53, 1319-27	14
610	Differential effects of short-chain fatty acids on head and neck squamous carcinoma cells. 2002 , 112, 645-50	9
609	In vivo characteristics of HPV-immortalized and carcinogen transformed oral keratinocytes. 2002 , 112, 1672-9	3
608	[Oesophageal cancer in patients with head and neck cancers: therapeutic implications]. 2002 , 127, 757-64	7
607	Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. 2002 , 74, 155-65	72
606	Retinoid, retinoic acid receptor beta and breast cancer. 2002 , 76, 167-73	48
605	Chemoprevention for pancreatic cancer. 2003 , 33, 27-41	10
604	General keynote: the impact of cancer chemoprevention. 2003 , 88, S56-8	21
603	Chemoprevention of head and neck cancer. 2003 , 5, 152-7	5
602	Molecularly targeted chemoprevention of lung cancer. 2003 , 4, 269-72	
601	Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer. <i>Oral Oncology</i> , 2003 , 39, 537-46	4-4 92
600	Cancer "photo-chemoprevention" with pulsed dye laser and celecoxib. 2003 , 32, 180-4	2
599	Second primary cancers in patients with laryngeal cancer: a population-based study. 2003 , 56, 427-35	68
598	Multiple primary tumours following head and neck cancer in southern England during 1961-98. 2003 , 32, 443-9	38
597	The role of laser vascular targeting and retinoic acid in oral cancer inhibition. 2003 , 113, 715-9	2
596	Dietary antioxidant intake in patients at risk for second primary cancer. 2003 , 113, 1487-93	10
595	The development of CpG island methylation biomarkers using restriction landmark genomic scanning. 2003 , 983, 110-9	12
594	Phenethyl isothiocyanate inhibits nitrosamine carcinogenesis in a model for study of oral cancer chemoprevention. 2003 , 202, 147-52	42

593	Cyclin D1 as a target for chemoprevention. 2003 , 41 Suppl 1, S155-61	33
592	Lung cancer chemoprevention: moving from concept to a reality. 2003 , 41 Suppl 1, S163-74	13
591	Chemoprevention of lung cancer: current status and future prospects. 2003 , 42 Suppl 1, S71-9	16
590	Sensitivity of human tumor cells to retinoids or combined treatment with retinoids and ionizing radiation is not dependent on RAR-beta 2 induction. 2003 , 179, 401-9	
589	Homozygous deletion of the CRABPI gene in AB1 embryonic stem cells results in increased CRABPII gene expression and decreased intracellular retinoic acid concentration. 2003 , 411, 159-73	23
588	Nonsmall-cell lung cancer: chemoprevention studies. 2003 , 15, 405-20	5
587	Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial. 2003 , 49, 83-90	83
586	Chemoprevention of lung cancer. 2003 , 4, 659-69	46
585	Lung Cancer. 2003 ,	11
584	Modified fatty acids and their possible therapeutic targets in malignant diseases. 2003 , 7, 663-77	16
583	Fenretinide: a prototype cancer prevention drug. 2003 , 12, 1829-42	42
582	Radiotherapy of early-stage glottic cancer: analysis of factors affecting prognosis. 2003 , 112, 904-11	29
581	Topical chemoprevention of oral cancer with tretinoin "biofilm". 2003 , 129, 869-73	11
580	New approaches to cancer therapy. 2003 , 14, 813-6	5
579	The use of genetic markers in the clinical care of patients with head and neck cancer. 2003 , 129, 363-6	12
578	Drugs for preventing lung cancer in healthy people. 2003 , CD002141	29
577	Chemoprevention of cancer--focusing on clinical trials. 2003 , 33, 421-42	51
576	Predicting success in cancer prevention trials. 2003 , 95, 178-9	10

575	An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. 2003 , 21, 4546-52	119
574	Retinoid Targets in Cancer Therapy and Chemoprevention. 2003 , 2, 149-155	30
573	Surrogate end-point biomarker analysis in a retinol chemoprevention trial in current and former smokers with bronchial dysplasia. 2003 , 23, 1607	4
572	Effects of local all-trans-retinoic acid delivery on experimental atherosclerosis in the rabbit carotid artery. 2003 , 57, 544-53	26
571	[First results on the influence of polymorphisms at glutathione S-transferase, cytochrome P450, and tumor necrosis factor gene loci on the development of multiple head and neck cancer]. 2003 , 82, 25-30	11
570	The molecular biology of mucosal field cancerization of the head and neck. 2003 , 14, 363-9	116
569	Prevention of lung cancer: summary of published evidence. 2003 , 123, 50S-59S	31
568	Bexarotene is a new treatment option for lymphomatoid papulosis. 2003 , 206, 142-7	48
567	Teachable moments for promoting smoking cessation: the context of cancer care and survivorship. 2003 , 10, 325-33	182
566	Lung cancer prevention: the guidelines. 2003 , 123, 60S-71S	29
565	Head and neck cancer. 2003 , 207-216	
564	Prevention and Early Detection of Lung Cancer. 2003 , 256-279	
563	Chemoprevention of Oral Premalignant Lesions. 2003 , 261-269	4
562	Cancer chemoprevention drug targets. 2003 , 4, 45-54	31
561	Chemoprevention of Tumors: The Role of RAR-Beta. 2003 , 18, 78-81	2
560	Ongoing and Future Clinical Nutrition Research Needs. 305-310	
559	. 2004 ,	
558	13-cis retinoic acid in head and neck cancer chemoprevention: results of a randomized trial from the Italian Head and Neck Chemoprevention Study Group. 2004 , 11, 1297	1

557	Handbook of Clinical Nutrition and Aging. 2004 ,	4
556	Retinoids in cancer chemoprevention. 2004 , 4, 285-98	112
555	Principles of Molecular Oncology. 2004 ,	6
554	Effects of acyclic retinoid on growth, cell cycle control, epidermal growth factor receptor signaling, and gene expression in human squamous cell carcinoma cells. 2004 , 10, 1130-40	39
553	Dietary carotenoids, connexins and cancer: what is the connection?. 2004 , 32, 985-9	23
552	Novel management of oral cancer: a paradigm of predictive oncology. 2004 , 2, 233-42	27
551	Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. 2004 , 10, 3607-13	135
550	Retinoic acid increases the expression of p53 and proapoptotic caspases and sensitizes keratinocytes to apoptosis: a possible explanation for tumor preventive action of retinoids. 2004 , 64, 6542-8	90
549	Chemoprevention of oral squamous cell carcinomas. 2004 , 27, 187-93	9
548	Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy. 2004 , 10, 2570-7	57
547	Advances in chemoprevention of head and neck cancer. 2004 , 9, 302-11	28
546	Nutrition and cancer prevention: a multidisciplinary perspective on human trials. 2004 , 24, 223-54	38
545	Bioactive carotenoids: potent antioxidants and regulators of gene expression. 2004 , 9, 181-91	59
544	Promoter methylation of retinoic acid receptor beta 2 and the development of second primary lung cancers in non-small-cell lung cancer. 2004 , 22, 3443-50	34
543	NSAIDs for the chemoprevention of oral cancer: promise or pessimism?: Commentary re J. L. Mulshine et al., randomized, double-blind, placebo-controlled, phase IIB trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin. Cancer Res., 10: 1565-1573, 2004 . 2004 , 10, 1561-4	11
542	Retinoids in lung cancer: friend, foe, or fellow traveler?. 2004 , 22, 3435-7	10
541	Polyamines and cancer: old molecules, new understanding. 2004 , 4, 781-92	847
540	Induction of apoptosis in oral cancer cells: agents and mechanisms for potential therapy and prevention. <i>Oral Oncology</i> , 2004 , 40, 461-73	4.4 69

539	Immunohistochemical expression of vascular endothelial growth factor correlates with positive surgical margins and recurrence in T1 and T2 squamous cell carcinoma (SCC) of the lower lip. <i>Oral Oncology</i> , 2004 , 40, 941-7	4.4	24
538	Focus on head and neck cancer. 2004 , 5, 311-6		299
537	Novel agents and incremental advances in the treatment of head and neck cancer. 2004 , 31, 3-10		12
536	Chemoprevention of head and neck cancer. 2004 , 31, 769-77		4
535	Glutathione S-transferase M1 or T1 null genotype as a risk factor for developing multiple primary neoplasms in the upper aero-digestive tract, in Indian males using tobacco. <i>Oral Oncology</i> , 2004 , 40, 84-91	4.4	14
534	Chemoprevention of cancer. 2004 , 54, 150-80		212
533	13-cis Retinoic acid ameliorates benzoyl peroxide-induced oxidative stress and hyperproliferative response in murine skin: a chemopreventive study. <i>Cancer Detection and Prevention</i> , 2004 , 28, 200-7		7
532	Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. 2004 , 111, 679-92		226
531	Stage-specific effect of N-(4-hydroxyphenyl)retinamide on cell growth in squamous cell carcinogenesis. 2004 , 40, 12-23		7
530	Stem cell origin of cancer and differentiation therapy. 2004 , 51, 1-28		509
529	Prevention of head and neck cancer: current status and future prospects. 2004 , 28, 265-86		11
528	Chemoprevention in lung cancer. 2004 , 28, 287-306		3
527	Suppression of Parathyroid Hormone-related Protein Expression by all trans-Retinoic Acid in Human Oral Squamous Carcinoma Cells (HSC-3). 2004 , 46, 550-557		
526	Novel treatments in non-small cell lung cancer. 2004 , 18, 245-67		10
525	The proteasome inhibitor MG132 attenuates retinoic acid receptor trans-activation and enhances trans-repression of nuclear factor kappaB. Potential relevance to chemo-preventive interventions with retinoids. 2004 , 3, 8		20
524	Laser assisted topical 'biofilm' chemoprevention of oral cancer. 2004 , 215, 29-34		4
523	Chemoprevention of lung cancer. 2004 , 10, 279-83		24
522	Surgical treatment of squamous cell carcinoma of the hypopharynx: analysis of treatment results, failure patterns, and prognostic factors. 2004 , 118, 443-9		27

521	Designing a randomized phase I/II prostate cancer chemoprevention trial using 1alpha-hydroxy-24-ethyl-cholecalciferol, an analogue of vitamin D3. 2004 , 10, 357-67		7
520	Application of retinoids in the treatment of renal cell carcinoma--a futile effort?. 2004 , 15, 819-24		6
519	Chemoprevention of head and neck cancer with retinoids: a negative result. 2005 , 131, 198-203		21
518	Lung cancer: genetics of risk and advances in chemoprevention. 2005 , 11, 265-71		24
517	Microsatellite polymorphisms in the epidermal growth factor receptor (EGFR) gene and the transforming growth factor-alpha (TGFA) gene and risk of oral cancer in Puerto Rico. 2005 , 15, 343-7		26
516	Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up. 2005 , 131, 304-7		36
515	Profiling early head and neck cancer. 2005 , 5, 127-35		345
514	Laser-assisted low-dose retinoic acid in oral cancer chemoprevention. 2005 , 115, 283-6		3
513	COX-2 expression correlates with VEGF-C and lymph node metastases in patients with head and neck squamous cell carcinoma. 2005 , 18, 153-60		69
512	Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2. 2005 , 18, 485-94		48
511	Novel strategies for the early detection and prevention of lung cancer. 2005 , 32, 259-68		34
510	Association between polymorphisms of the GPX1 gene and second primary tumours after index squamous cell cancer of the head and neck. <i>Oral Oncology</i> , 2005 , 41, 455-61	4.4	18
509	Molecular analysis of paired tumours: time to start treating the field. <i>Oral Oncology</i> , 2005 , 41, 916-26	4.4	12
508	Nonclassical retinoids and lung carcinogenesis. 2005 , 6, 237-44		18
507	Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results. 2005 , 115, 625-9		68
506	Transcriptional regulation of connexin 43 expression by retinoids and carotenoids: similarities and differences. 2005 , 43, 75-85		26
505	Mechanisms of the self/non-self-survey in the defense against cancer: potential for chemoprevention?. 2005 , 56, 5-22		8
504	Retinoids as chemoprevention for head and neck cancer: where do we go from here?. 2005 , 55, 143-52		33

503	Adjuvant treatment of locally-advanced head and neck tumours. 2005 , 7, 183-8		4
502	Chemopreventive effect of piperine on mitochondrial TCA cycle and phase-I and glutathione-metabolizing enzymes in benzo(a)pyrene induced lung carcinogenesis in Swiss albino mice. 2005 , 271, 101-6		37
501	Chemoprevention of lung cancer. <i>Recent Results in Cancer Research</i> , 2005 , 166, 145-65	1.5	2
500	Chemoprevention of colorectal cancer: ready for routine use?. <i>Recent Results in Cancer Research</i> , 2005 , 166, 213-30	1.5	26
499	Chemoprevention of colorectal cancer: ready for routine use?. 2005 , 5, 517-25		14
498	A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis. 2005 , 97, 1645-51		48
497	The role of COX-2 in oral cancer development, and chemoprevention/ treatment of oral cancer by selective COX-2 inhibitors. 2005 , 11, 1771-7		30
496	Females with paired occurrence of cancers in the UADT and genital region have a higher frequency of either Glutathione S-transferase M1/T1 null genotype. 2005 , 4, 6		3
495	Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. 2005 , 68, 635-43		152
494	Cancer prevention: the importance of accurate risk assessment. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 1357-8	4	1
493	An apple a day...does it really keep the doctor away? The current state of cancer chemoprevention. 2005 , 97, 468-70		10
492	Chemoprevention of lung cancer: concepts and strategies. 2005 , 5, 549-65		4
491	Tumorigenicity issues of embryonic carcinoma-derived stem cells: relevance to surgical trials using NT2 and hNT neural cells. 2005 , 14, 29-43		64
490	A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. 2005 , 97, 481-8		180
489	Second field tumors: a new opportunity for cancer prevention?. 2005 , 10, 493-500		66
488	Cellular retinoic acid binding protein I: expression and functional influence in renal cell carcinoma. 2005 , 26, 313-23		15
487	Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary?. 2005 , 11, 6608-14		80
486	Retinoid receptor mRNA expression profiles in human bladder cancer specimens. 2005 , 26, 1041		

485	How should we move the field of chemopreventive agent development forward in a productive manner?. <i>Recent Results in Cancer Research</i> , 2005 , 166, 113-24	1.5	15
484	Effects of retinoic acid on retinal pigment epithelium from excised membranes from proliferative vitreoretinopathy. 2005 , 21, 44-54		21
483	Upregulation of connexin 43 by retinoids but not by non-provitamin A carotenoids requires RARs. 2005 , 52, 105-13		18
482	Oral cancer prevention and the evolution of molecular-targeted drug development. 2005 , 23, 346-56		141
481	Preoperative radiochemotherapy and radical resection for stages II to IV oral and oropharyngeal cancer: grade of regression as crucial prognostic factor. 2005 , 34, 262-7		21
480	Connexins as targets for cancer chemoprevention and chemotherapy. 2005 , 1719, 146-60		86
479	Oral cancer: leukoplakia and squamous cell carcinoma. 2005 , 49, 143-65, ix		30
478	Chemoprevention in lung carcinogenesis--an overview. 2005 , 41, 1990-2002		12
477	Cancer chemoprevention--an update on a (still) novel and exciting field of oncology. 2005 , 41, 1831-2		1
476	Hypoxia-induced tumor angiogenic pathway in head and neck cancer: an in vivo study. 2005 , 225, 297-304		48
475	Principles of cancer prevention. 2005 , 21, 229-35		5
474	Chemoprevention: a primary cancer prevention strategy. 2005 , 21, 243-51		12
473	Expression and functional influence of cellular retinoic acid-binding protein II in renal cell carcinoma. 2005 , 75, 269-76		8
472	Pathogenesis of lung cancer: 100 year report. 2005 , 33, 216-23		104
471	Chemoprevention of squamous cell carcinoma of the oral cavity. 2006 , 39, 349-63		10
470	Prevention of breast cancer: current state of the science and future opportunities. 2006 , 15, 1583-600		18
469	Oral cancer prevention. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2006 , 18, 493-511	3.4	10
468	UVB-mediated induction of cytokines and growth factors in pterygium epithelial cells involves cell surface receptors and intracellular signaling. 2006 , 47, 2430-7		108

467	Coxibs and cancer prevention. 2006 , 47 Suppl 1, S76-81	10
466	Chemoprevention of Nonmelanoma Skin Cancer with Systemic Retinoids. 2006 , 32, 562-568	2
465	Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. 2006 , 32, 562-8	79
464	Isotretinoin--unapproved indications/uses and dosage: a physician's reference. 2006 , 45, 772-7	12
463	Loss of heterozygosity at 15q21.3 correlates with occurrence of metastases in head and neck cancer. 2006 , 19, 1462-9	14
462	Peroxisome proliferator-activated receptor gamma in malignant diseases. 2006 , 58, 1-14	101
461	Chemopreventive efficacy of all-trans-retinoic acid in biodegradable microspheres against epithelial cancers: results in a 4-nitroquinoline 1-oxide-induced oral carcinogenesis model. 2006 , 320, 45-52	5
460	The liver as a target organ of retinoids. 2006 , 36, 248-54	8
459	Management of laryngeal dysplasia: a review. 2006 , 263, 843-52	66
458	Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma. 2006 , 448, 768-75	51
457	Curcumin down regulates smokeless tobacco-induced NF-kappaB activation and COX-2 expression in human oral premalignant and cancer cells. 2006 , 228, 1-15	88
456	Clinical significance of altered expression of retinoid receptors in oral precancerous and cancerous lesions: relationship with cell cycle regulators. 2006 , 118, 1077-89	17
455	Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. 2006 , 98, 441-50	188
454	Secondary free-tissue reconstruction for metachronous tumors of the head and neck: techniques, results, and outcomes. 2006 , 22, 267-72	4
453	Chemoprevention of colorectal cancer: two steps forward, one step back?. 2006 , 2, 697-704	12
452	The retinoic acid paradox in cancer chemoprevention. 2006 , 98, 426-7	28
451	Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. 2006 , 12, 3661-97	235
450	American Society of Preventive Oncology Distinguished Career Achievement Lecture 2006--Enjoy the journey: the long and winding road of chemoprevention agent development. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 2038-41	4 3

449	Fenretinide activity in retinoid-resistant oral leukoplakia. 2006 , 12, 3109-14		43
448	Reducing the "risk" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. 2006 , 66, 2893-903		32
447	Head and Neck Cancer. 2006 , 535-551		1
446	Organ-specific expression profiles of rat mammary gland, liver, and lung tissues treated with taretin, 9-cis retinoic acid, and 4-hydroxyphenylretinamide. 2006 , 5, 1060-72		21
445	A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 1914-9	4	30
444	American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. 2006 , 24, 3693-704		358
443	Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. 2007 , 67, 10538-45		119
442	Squamous Cell Carcinoma. 2007 , 1-4		
441	Current and future clinical strategies in colon cancer prevention and the emerging role of chemoprevention. 2007 , 13, 2274-82		41
440	Proliferative changes in the bronchial epithelium of former smokers treated with retinoids. 2007 , 99, 1603-12		15
439	Chemoprevention clinical trials: it is time to turn success into progress. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 1531-2	4	3
438	Primary lung cancer and extrapulmonary malignancy. 2007 , 32, 653-8		18
437	Treatment with 1-alpha,25-dihydroxyvitamin D3 (vitamin D3) to inhibit carcinogenesis in the hamster buccal pouch model. 2007 , 133, 1149-52		30
436	Cancer Chemoprevention. 2007 ,		
435	Translational approaches for the prevention of estrogen receptor-negative breast cancer. 2007 , 16, 203-15		12
434	Status of primary tumour surgical margins in squamous head and neck cancer: prognostic implications. 2007 , 15, 74-81		40
433	Chemoprevention of squamous cell carcinoma of the head and neck. 2007 , 19, 180-7		18
432	Tumor-suppressive activity of retinoic acid receptor-beta in cancer. 2007 , 253, 14-24		95

431	Retinoids and Carotenoids in Dermatology. 2007 ,		10
430	Retinoids for preventing the progression of cervical intra-epithelial neoplasia. 2007 , CD003296		5
429	Combinational treatment with retinoic acid derivatives in non-small cell lung carcinoma in vitro. 2007 , 22 Suppl, S52-60		15
428	Cyclooxygenase-2 as target for chemopreventive interventions: new approaches. 2007 , 3, 153-61		5
427	29 Chemoprevention. 2007 ,		
426	Biopharmaceutics of 13-cis-retinoic acid (isotretinoin) formulated with modified beta-cyclodextrins. 2007 , 341, 238-45		17
425	Moving toward bioadjuvant approaches to head and neck cancer prevention. 2007 , 69, S132-5		4
424	Morphogens, morphostats, microarchitecture and malignancy. 2007 , 7, 464-74		90
423	Chemoprevention of colorectal cancer - a new target needed?. 2007 , 9, 397-401		12
422	Antioxidant status of oral mucosal tissue and plasma levels in smokers and non-smokers. 1999 , 28, 360-3		9
421	Effects of cisplatin, alpha-interferon, and 13-cis retinoic acid on the expression of Fas (CD95), intercellular adhesion molecule-1 (ICAM-1), and epidermal growth factor receptor (EGFR) in oral cancer cell lines. 2007 , 36, 177-83		16
420	Expression of Ki-67 and p53 in cutaneous free flaps used to reconstruct soft tissue defects following resection of oral squamous cell carcinoma. <i>Oral Oncology</i> , 2007 , 43, 263-71	4.4	8
419	Survival of second and multiple primary tumors in patients with oral cavity squamous cell carcinoma in the betel quid chewing area. <i>Oral Oncology</i> , 2007 , 43, 811-9	4.4	62
418	Down-regulation of retinol binding protein 5 is associated with aggressive tumor features in hepatocellular carcinoma. 2007 , 133, 929-36		7
417	Glottic versus supraglottic tumors: differential molecular profile. 2008 , 265, 79-84		10
416	The accuracy of cancer diagnoses as reported in families with head and neck cancer: a case-control study. 2008 , 20, 309-14		5
415	Increased expression of epidermal growth factor receptor in normal epithelium adjacent to head and neck carcinomas independent of tobacco and alcohol abuse. 1998 , 4, 4-8		26
414	Case-control study and meta-analysis of SULT1A1 Arg213His polymorphism for gene, ethnicity and environment interaction for cancer risk. 2008 , 99, 1340-7		32

413	Chemoprevention of colorectal neoplasia: the potential for personalized medicine. 2008 , 134, 1224-37	90
412	[Risk factors for cancers of the oral cavity, pharynx (cavity excluded) and larynx]. 2008 , 37, 1229-40	14
411	Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy. 2008 , 146, 440-446	48
410	Second primary malignancies in squamous cell carcinomas of the tongue and larynx: an analysis of incidence, pattern, and outcome. 2008 , 71, 86-91	31
409	Head and neck cancer chemoprevention gets a shot in the arm. 2008 , 26, 345-7	20
408	A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. 2008 , 1, 339-48	20
407	Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial. 2008 , 31, 25-33	29
406	Dietary terpenoids and prostate cancer chemoprevention. 2008 , 13, 3457-69	25
405	[Chemoprevention in head and neck cancer and lung cancer]. 2009 , 96 Suppl 1, S25-34	
404	Chemotherapy in Head and Neck Cancer. 2009 , 181-188	1
403	Oral cancer prevention advances with a translational trial of green tea. 2009 , 2, 919-21	9
402	Food, nutrition and oral cancer. 2009 , 273-295	21
401	Retinoid chemoprevention trials: cyclin D1 in the crosshairs. 2009 , 2, 3-6	8
400	Alcohol and tobacco use prediagnosis and postdiagnosis, and survival in a cohort of patients with early stage cancers of the oral cavity, pharynx, and larynx. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 3368-74	4 113
399	Overexpression of lecithin:retinol acyltransferase in the epithelial basal layer makes mice more sensitive to oral cavity carcinogenesis induced by a carcinogen. 2009 , 8, 1212-3	12
398	Photodynamic therapy for head and neck dysplasia and cancer. 2009 , 135, 784-8	83
397	American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. 2009 , 27, 986-93	50
396	Cancer prevention research: back to the future. 2009 , 2, 503-13	5

395	Cancer prevention: from 1727 to milestones of the past 100 years. 2009 , 69, 5269-84	94	
394	Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1. 2009 , 284, 345-353	23	
393	Concordant DNA methylation in synchronous colorectal carcinomas. 2009 , 2, 814-22	34	
392	All-trans and 13-cis-retinoic acids are normal constituents of human blood formed from all-trans-retinyl palmitate. 1991 , 49, 283-4		
391	Human leukemic K562 cells treated with cytosine arabinoside: enhancement of erythroid differentiation by retinoic acid and retinol. 1998 , 61, 295-301	10	
390	In vitro treatment with retinoids decreases bcl-2 protein expression and enhances dexamethasone-induced cytotoxicity and apoptosis in multiple myeloma cells. 1999 , 62, 143-8	13	
389	All-trans retinoic acid at low concentration directly stimulates normal adult megakaryocytopoiesis in the presence of thrombopoietin or combined cytokines. 1999 , 63, 149-53	12	
388	Modulation of p53, c-fos, RARE, cyclin A, and cyclin D1 expression in human leukemia (HL-60) cells exposed to arsenic trioxide. 2009 , 331, 207-14	22	
387	Molecular targets for cancer chemoprevention. 2009 , 8, 213-25	113	
386	Mutant p53 and cyclin A1 protein expression in primary laryngeal squamous cell carcinomas do not correlate to second primary tumours of the head and neck. 2009 , 79, 48-54	6	
385	Can cervical dysplasia and cancer be prevented with nutrients?. 1998 , 56, 9-16	19	
384	Evolution of clinical trials in head and neck cancer. 2009 , 71, 29-42	18	
383	Perspectives for cancer prevention with natural compounds. 2009 , 27, 2712-25	395	
382	Vitamin A/retinoids signalling in the human lung. 2009 , 66, 1-7	20	
381	Cancer Prevention II. <i>Recent Results in Cancer Research</i> , 2009 ,	1.5	1
380	Multiple Primary Malignancies. 2009 ,		1
379	Epigenetic silencing of CRABP2 and MX1 in head and neck tumors. 2009 , 11, 1329-39	57	
378	Second-line chemotherapy in head and neck cancer: what should we expect?. 2009 , 9, 269-73	4	

377	All-trans retinoic acid remodels extracellular matrix and suppresses laminin-enhanced contractility of cultured human retinal pigment epithelial cells. 2009 , 88, 900-9		27
376	Detection and screening of oral cancer and pre-cancerous lesions. 2009 , 72, 227-33		32
375	Indications and outcomes for mandibular reconstruction using sequential bilateral fibula flaps. 2010 , 126, 1539-1547		12
374	Cancer prevention with natural compounds. 2010 , 37, 258-81		35 ^o
373	Impact of second primary esophageal or lung cancer on survival of patients with head and neck cancer. <i>Oral Oncology</i> , 2010 , 46, 249-54	4.4	45
372	Analysis of Ki-67 expression in oral squamous cell carcinoma: why Ki-67 is not a prognostic indicator. <i>Oral Oncology</i> , 2010 , 46, 525-30	4.4	3 ¹
371	Criteria to define true second primary oral squamous cell carcinoma. <i>Oral Oncology</i> , 2010 , 46, 834	4.4	6
37 ^o	Mechanism of inhibition of MMTV-neu and MMTV-wnt1 induced mammary oncogenesis by RARalpha agonist AM580. 2010 , 29, 3665-76		20
369	Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment. 2003 , 113, 1687-702		42
368	Prevention of Lung Cancer: Future Perspective with Natural Compounds. 2010 , 69, 1		5
367	Epidemiology, Pathogenesis, and Prevention of Head and Neck Cancer. 2010 ,		5
366	Dichloromethane fraction from <i>Gardenia jasminoides</i> : DNA topoisomerase 1 inhibition and oral cancer cell death induction. 2010 , 48, 1354-60		11
365	Mortality in the randomized, controlled lung intergroup trial of isotretinoin. 2010 , 3, 738-44		9
364	Chemopreventive potential of natural compounds in head and neck cancer. 2010 , 62, 973-87		49
363	In vitro and in vivo studies demonstrate anticancer property of root extract of <i>Polygala senega</i> . 2010 , 3, 188-96		11
362	Dose response of retinol and isotretinoin in the prevention of nonmelanoma skin cancer recurrence. 2010 , 62, 1058-66		14
361	Retinoic acid and its binding protein modulate apoptotic signals in hypoxic hepatocellular carcinoma cells. 2010 , 295, 229-35		9
36 ^o	Different patterns of second primary malignancy in patients with squamous cell carcinoma of larynx and hypopharynx. 2010 , 31, 168-74		23

359	Metoda fotodynamiczna w diagnostyce i terapii guzów głowy i szyi. 2011 , 1, 50-58	
358	All trans retinoic acid and cancer. 2011 , 33, 241-9	133
357	The chemopreventive properties and therapeutic modulation of green tea polyphenols in oral squamous cell carcinoma. 2011 , 2011, 403707	15
356	Modulatory influence of <i>Phyllanthus niruri</i> on oxidative stress, antioxidant defense and chemically induced skin tumors. 2011 , 30, 43-53	4
355	Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. 2011 , 4, 185-93	34
354	An overview of the molecular pathology of head and neck cancer, and its clinical implications. 2011 , 57, 132-49	4
353	Ki-67 expression in non-tumour epithelium adjacent to oral cancer as risk marker for multiple oral tumours. 2011 , 17, 340-1; author reply 341	
352	A phase I trial of bexarotene in combination with docetaxel in patients with advanced solid tumors. 2011 , 12, 231-6	9
351	Second primary tumors in patients with head and neck cancer. 2011 , 13, 132-7	54
350	Reuben Lotan, Ph.D. (1946-2011): in memoriam. 2011 , 12, 1015-7	
349	Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes. 2011 , 46, 884-91	78
348	Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. 2011 , 4, 311-23	41
347	Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma. 2011 , 4, 230-7	47
346	RAR-beta expression is associated with early volumetric changes to radiation therapy in cervical cancer. 2011 , 71, 11-8	4
345	Model examination of chemoprevention with retinoids in squamous cell carcinomas of the head and neck region and suitable biomarkers for chemoprevention. 2011 , 39, 1083-97	1
344	Impact of interval and combination therapies on the management of actinic keratosis: review and clinical considerations. 2011 , 22, 288-97	16
343	Clinical Cancer Prevention. <i>Recent Results in Cancer Research</i> , 2011 ,	1.5 3
342	Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. 2012 , 18, 3705-13	45

341	Retinoids, carotenoids, and tocopherols in breast adipose tissue and serum of benign breast disease and breast cancer patients. 2012 , 64, 956-63		13
340	HPV analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. 2012 , 36, 142-8		69
339	Effectiveness of narrow band imaging in patients with oral squamous cell carcinoma after treatment. <i>Head and Neck</i> , 2012 , 34, 155-61	4.2	33
338	Incidence of second primary malignancies in patients with treated head and neck cancer: a comprehensive review of literature. 2012 , 28, 1899-909		37
337	Second malignant neoplasms: assessment and strategies for risk reduction. 2012 , 30, 3734-45		190
336	Chemoprevention: making it a success story for controlling human cancer. 2012 , 326, 123-7		34
335	All-trans-retinoic acid inhibits growth of head and neck cancer stem cells by suppression of Wnt/ β -catenin pathway. 2012 , 48, 3310-8		78
334	Drugs for preventing lung cancer in healthy people. 2012 , 10, CD002141		29
333	Multiple pathway-based genetic variations associated with tobacco related multiple primary neoplasms. <i>PLoS ONE</i> , 2012 , 7, e30013	3.7	13
332	p53 Mutation and Multiple Primary Oral Squamous Cell Carcinomas. 2012 ,		
331	Two hundred years of cancer research. <i>New England Journal of Medicine</i> , 2012 , 366, 2207-14	59.2	172
330	Clinical presentation, endoscopic features, treatment and prognosis of synchronous upper gastrointestinal malignancies. 2012 , 13, 19-23		3
329	Molecular findings in oral premalignant fields: update on their diagnostic and clinical implications. 2012 , 18, 40-7		29
328	Recent advances in head and neck cancer. 2012 , 9, 96-103		3
327	Genetic sequence variants and the development of secondary primary cancers in patients with head and neck cancers. 2012 , 118, 1554-65		13
326	Systemic therapy in head and neck cancer: changing paradigm. 2013 , 4, 19-26		7
325	Oral premalignancy: the roles of early detection and chemoprevention. 2013 , 46, 579-97		27
324	Prospects for Chemoprevention of Colorectal Neoplasia. <i>Recent Results in Cancer Research</i> , 2013 ,	1.5	2

323	Special Adjuncts to Treatment. 2013 , 1735-1783		4
322	Patterns of recurrence and second primary tumors in oral squamous cell carcinoma treated with surgery alone. 2013 , 29, 554-9		23
321	Second primary tumors and myeloperoxidase expression in buccal mucosal squamous cell carcinoma. 2013 , 116, 464-73		8
320	Molecular etiology of second primary tumors in contralateral tonsils of human papillomavirus-associated index tonsillar carcinomas. <i>Oral Oncology</i> , 2013 , 49, 244-8	4.4	39
319	E-cadherin in non-tumor epithelium adjacent to oral cancer as risk marker for the development of multiple tumors. 2013 , 51, 157-63		8
318	An animal model of buccal mucosa cancer and cervical lymph node metastasis induced by U14 squamous cell carcinoma cells. 2013 , 5, 1083-1088		8
317	Retinoids for preventing the progression of cervical intra-epithelial neoplasia. 2013 , CD003296		7
316	Targeted therapy for breast cancer prevention. 2013 , 3, 250		89
315	Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. 2013 , 31, 4179-87		76
314	Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials. <i>Recent Results in Cancer Research</i> , 2013 , 191, 67-93	1.5	33
313	Genetic sequence variants in vitamin D metabolism pathway genes, serum vitamin D level and outcome in head and neck cancer patients. 2013 , 132, 2520-7		12
312	Isotretinoin updates. <i>Dermatologic Therapy</i> , 2013 , 26, 377-89	2.2	23
311	Growth and differentiation factor 3 induces expression of genes related to differentiation in a model of cancer stem cells and protects them from retinoic acid-induced apoptosis. <i>PLoS ONE</i> , 2013 , 8, e70612	3.7	11
310	Oral field cancerization: an update on current concepts. 2014 , 8, 244		57
309	Methylation-associated gene silencing of RARB in areca carcinogens induced mouse oral squamous cell carcinoma. 2014 , 2014, 378358		22
308	Combination of 13-Cis retinoic acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice. 2014 , 155, 2377-90		14
307	Correction of all-trans retinoic acid deficiency in alcoholic cirrhosis lessens the excessive inflammatory monocyte response: a translational study. 2014 , 34, 343-52		8
306	Genetic relationship between multiple squamous cell carcinomas arising in the oral cavity. <i>Head and Neck</i> , 2014 , 36, 94-100	4.2	13

305	Molecular Determinants of Head and Neck Cancer. 2014 ,	2
304	Clinicopathologic parameters related to recurrence and locoregional metastasis in 180 oral squamous cell carcinomas. 2014 , 22, 55-62	12
303	Future prospective and current status of antioxidants in premalignant and malignant lesions of oral cavity. 2014 , 4, 198	2
302	All-trans retinoic acid induces DU145 cell cycle arrest through Cdk5 activation. 2014 , 33, 1620-30	20
301	Cancer chemoprevention is not a failure. 2014 , 35, 2154-5	16
300	Headway and hurdles in the clinical development of dietary phytochemicals for cancer therapy and prevention: lessons learned from vitamin A derivatives. 2014 , 16, 281-8	3
299	Development of new leukoplakias and leukoplakia-associated second/multiple primary oral cancers: A case report and literature review. 2014 , 26, 166-169	2
298	No evidence for active human papillomavirus (HPV) in fields surrounding HPV-positive oropharyngeal tumors. 2014 , 43, 137-42	32
297	The failure of cancer chemoprevention. 2014 , 35, 974-82	54
296	Retinoic acid actions through mammalian nuclear receptors. 2014 , 114, 233-54	84
295	Asymmetrical proliferative pattern loss during malignant transformation of the oral mucosa. 2014 , 43, 507-13	11
294	Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer. 2014 , 6, 96-109	29
293	PPAR γ in head and neck cancer prevention. <i>Oral Oncology</i> , 2014 , 50, 924-9	4.4 19
292	Advances in the Use of Retinoids in Cancer Therapy and Prevention. 2015 , 557-574	1
291	Impaired aldehyde dehydrogenase 1 subfamily member 2A-dependent retinoic acid signaling is related with a mesenchymal-like phenotype and an unfavorable prognosis of head and neck squamous cell carcinoma. 2015 , 14, 204	13
290	. 2015 ,	8
289	Minireview: Familiar Faces in Unfamiliar Places: The Emerging Role of Nuclear Receptors in Lung Cancer. 2015 , 29, 1675-83	2
288	Molecular events in relapsed oral squamous cell carcinoma: Recurrence vs. secondary primary tumor. <i>Oral Oncology</i> , 2015 , 51, 738-44	4.4 22

287	Molecular cancer prevention: Current status and future directions. 2015 , 65, 345-83		51
286	Synthetic retinoid interventions and outcomes in people with cancer or potentially malignant disorders of the upper aerodigestive tract: a systematic review and meta-analysis. 2015 , 8, 131-146		
285	Retinoic acid receptors: from molecular mechanisms to cancer therapy. 2015 , 41, 1-115		204
284	Surgical outcomes of pulmonary metastases from esophageal carcinoma diagnosed by both pathological and clinical criteria. 2015 , 45, 1127-33		13
283	Squamous Cell Carcinoma of the Skin?. 2015 ,		
282	Retinoid Chemoprevention: Who Can Benefit?. 2015 , 1, 391-400		10
281	Chemoprevention targets for tobacco-related head and neck cancer: past lessons and future directions. <i>Oral Oncology</i> , 2015 , 51, 557-64	4.4	19
280	[Clinical and paraclinical follow-up after radiotherapy for head and neck cancer]. 2015 , 19, 597-602		1
279	MicroRNA-10a is reduced in breast cancer and regulated in part through retinoic acid. 2015 , 15, 345		40
278	Prevention of head and neck squamous cell carcinoma: removing the "chemo" from "chemoprevention". <i>Oral Oncology</i> , 2015 , 51, 112-8	4.4	23
277	Albumin nanocapsules containing fenretinide: pre-clinical evaluation of cytotoxic activity in experimental models of human non-small cell lung cancer. 2015 , 11, 263-73		19
276	Prognostic factors, predictive markers and cancer biology: the triad for successful oral cancer chemoprevention. 2016 , 12, 2379-86		16
275	Suppressive function of low-dose deguelin on the invasion of oral cancer cells by downregulating tumor necrosis factor alpha-induced nuclear factor-kappa B signaling. <i>Head and Neck</i> , 2016 , 38 Suppl 1, E524-34	4.2	22
274	Cancer Prevention: Lessons Learned and Future Directions. 2016 , 2, 713-722		11
273	Pattern of failure in 5001 patients treated for glottic squamous cell carcinoma with curative intent - A population based study from the DAHANCA group. 2016 , 118, 257-66		25
272	Cetuximab activity in dysplastic lesions of the upper aerodigestive tract. <i>Oral Oncology</i> , 2016 , 53, 60-6	4.4	7
271	Targeting Retinoid Receptors to Treat Schizophrenia: Rationale and Progress to Date. 2016 , 30, 269-80		10
270	A Rational Approach for the Use of NSAIDs and/or Aspirin in Cancer Prevention in the Near Future: Balancing Risk and Benefits□ 2016 , 241-257		

269	Nasopharyngeal Carcinoma. 2016 , 629-648.e4	2
268	Larynx and Hypopharynx Cancer. 2016 , 649-672.e4	2
267	Overview. 2016 , 561-569.e3	
266	Head and Neck Cancer Prevention. 2016 , 59-76	1
265	Lessons learned from cancer prevention studies with nutrients and non-nutritive dietary constituents. 2016 , 60, 1239-50	20
264	NSAIDs and Aspirin. 2016 ,	4
263	NonSmall Cell Lung Cancer. 2016 , 809-842.e8	
262	Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane. 2016 , 9, 547-57	56
261	Open questions and novel concepts in oral cancer surgery. 2016 , 273, 1975-85	8
260	Differential diagnosis between primary lung squamous cell carcinoma and pulmonary metastasis of head and neck squamous cell carcinoma. 2016 , 16, 403-10	6
259	Potential strategies to ameliorate risk of radiotherapy-induced second malignant neoplasms. 2016 , 37-38, 65-76	22
258	Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. 2016 , 2, 209-16	89
257	Retinoids and rexinoids in cancer prevention: from laboratory to clinic. 2016 , 43, 49-64	102
256	Oral Cancer Chemoprevention--The End of EPOC, the Beginning of an Epoch of Molecular Selection. 2016 , 2, 178-9	13
255	Principles of Medical Oncology. 2017 , 1-9	
254	Clonal analysis as a prognostic factor in multiple oral squamous cell carcinoma. <i>Oral Oncology</i> , 2017 , 67, 131-137	4-4 8
253	Follow-up of oral and oropharyngeal cancer using narrow-band imaging and high-definition television with rigid endoscope to obtain an early diagnosis of second primary tumors: a prospective study. 2017 , 274, 2529-2536	13
252	Topical oral cavity chemoprophylaxis using isotretinoin rinse: A 15-year experience. 2017 , 127, 1595-1599	3

251	Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). 2017 , 123, 4653-4662		17
250	SR 11302, an AP-1 Inhibitor, Reduces Metastatic Lesion Formation in Ex Vivo 4D Lung Cancer Model. 2017 , 10, 95-103		8
249	Cancer Chemoprevention: What Have we Learned?. 2017 , 3, 409-422		
248	Impact of combined modality treatment with radiotherapy and S-1 on T2N0 laryngeal cancer: Possible improvement in survival through the prevention of second primary cancer and distant metastasis. <i>Oral Oncology</i> , 2017 , 71, 54-59	4.4	12
247	Cancer and Chemoprevention: An Overview. 2017 ,		2
246	Metastatic squamous cell carcinoma of colon from esophageal cancer. 2017 , 6, 11		6
245	Integrative Medicine in Head and Neck Cancer. 2017 , 156, 228-237		15
244	GRIM-19: A master regulator of cytokine induced tumor suppression, metastasis and energy metabolism. 2017 , 33, 1-18		12
243	EGFR copy number alterations in primary tumors, metastatic lymph nodes, and recurrent and multiple primary tumors in oral cavity squamous cell carcinoma. 2017 , 17, 592		9
242	Facial flushing after alcohol intake as a predictor for a high risk of synchronous or metachronous cancer of the upper gastrointestinal tract. 2017 , 47, 1123-1128		6
241	Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck. <i>Cancers</i> , 2017 , 9,	6.6	15
240	Chemoprevention Trials. 2017 ,		1
239	Do we need a different staging system for tongue and gingivobuccal complex squamous cell cancers?. <i>Oral Oncology</i> , 2018 , 78, 64-71	4.4	7
238	Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer. 2018 , 110,		15
237	Chemoprevention of Lung Cancer and Management of Early Lung Cancer. 2018 , 69-81.e5		
236	Metachronous second primary malignancy in head and neck cancer patients: is five years of follow-up sufficient?. 2018 , 44, 220-224		5
235	Chemoprevention of Head and Neck Cancers: Does It Have Only One Face?. 2018 , 2018, 9051854		8
234	Outcomes for patients with second primary malignancy after primary surgical treatment for early-stage squamous cell carcinoma of the oral cavity. <i>Head and Neck</i> , 2018 , 40, 2347-2352	4.2	1

233	Sextuple Tumors in Head and Neck Area: Evidence of Field Cancerization. 2018 , 2018, 8428395		
232	Current thinking in management of the neck (including contralateral neck) in ipsilateral recurrent or second primary oral squamous cell carcinoma. 2019 , 57, 711-715		2
231	Survival of patients with head and neck cancer with metachronous multiple primary tumors is surprisingly favorable. <i>Head and Neck</i> , 2019 , 41, 1648-1655	4.2	12
230	Guidelines in the Management of Advanced Carcinoma of the Larynx. 2019 , 77-98		
229	Oncoproteomic and gene expression analyses identify prognostic biomarkers for second primary malignancy in patients with head and neck squamous cell carcinoma. 2019 , 32, 943-956		10
228	Carcinoma of the Larynx and Hypopharynx. 2019 ,		1
227	Pathological factors involved in local failure in squamous cell carcinoma of the oral cavity: retrospective study and proposal of a new clinical classification. 2019 , 48, 143-151		1
226	Curcumin gum formulation for prevention of oral cavity head and neck squamous cell carcinoma. 2019 , 129, 1597-1603		8
225	Asymmetrical proliferative pattern loss linked to cyclin D1 overexpression in adjacent non-tumour epithelium in oral squamous cell carcinoma. 2019 , 97, 12-17		10
224	Lifestyle and Cancer Prevention. 2020 , 337-374.e12		0
223	Porfimer sodium-mediated photodynamic therapy in patients with head and neck squamous cell carcinoma. 2020 , 29, 101627		11
222	Head and neck squamous cell carcinoma. 2020 , 6, 92		397
221	Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck. 2020 , 26, 5860-5868		4
220	Head and Neck Cancer Prevention by Phytochemicals: Current Status and Challenges. 2020 , 6, 85-102		2
219	Sarcomatoid variant of squamous carcinoma in recurrent and second primary tumors of the oral cavity. 2020 , 49, 914-919		2
218	Study of the Incidence, Clinicopathological Profile, and Management of Second Primary Tumors in Patients with Index Head and Neck Tumors. 2020 , 6, 53-60		
217	PS4DR: a multimodal workflow for identification and prioritization of drugs based on pathway signatures. 2020 , 21, 231		6
216	Most Cited Articles in Head and Neck Oncology. 2021 , 100, 1061S-1072S		

215	Definition of locally recurrent head and neck squamous cell carcinoma: a systematic review and proposal for the Odense-Birmingham definition. 2020 , 277, 1593-1599		8
214	Encyclopedia of Quality of Life and Well-Being Research. 2021 , 1-8		
213	General Introduction to Head and Neck Cancer: Etiology, Symptoms, Diagnosis, Staging, Prevention, and Treatment. 2021 , 1-50		
212	A cause-specific Cox model for second primary tumors in patients with head and neck cancer: A RONCDOC study. <i>Head and Neck</i> , 2021 , 43, 1881-1889	4.2	2
211	Early glottic cancer recurrence: A critical review on its current management. 2021 , 160, 103298		1
210	Precision and Immunoprevention Strategies for Tobacco-Related Head and Neck Cancer Chemoprevention. 2021 , 22, 52		1
209	All that glitters is not gold: Clinical implications from the genetic analysis of head and neck cancer recurrences. <i>Oral Oncology</i> , 2021 , 117, 105187	4.4	
208	Estimating the risks and benefits before salvage surgery for recurrent head and neck squamous cell carcinoma. 2021 , 47, 1718-1726		2
207	An active surveillance program in oral preneoplasia and translational oncology benefit. 2021 , 6, 764-772		0
206	Phytochemicals as Potential Chemopreventive and Chemotherapeutic Agents for Emerging Human Papillomavirus-Driven Head and Neck Cancer: Current Evidence and Future Prospects. 2021 , 12, 699044		2
205	Treatment Modality and Second Primary Tumors of the Head and Neck. 2021 , 83, 420-427		3
204	Approach to the Patient with Gas and Bloating. 723-734		1
203	Somatic Evolution in Neoplastic Progression and Cancer Prevention. 2011 , 111-127		4
202	Beta-carotene and Antioxidant Nutrients in Oral Cancer Prevention. 1995 , 235-247		5
201	Role of Vitamin A and Its Derivatives in the Treatment of Human Cancer. 1995 , 349-362		7
200	Inhibition of Chemical Carcinogenesis. 1995 , 73-122		7
199	Retinoids: Concepts for Separation of Desirable and Undesirable Effects in the Treatment or Prevention of Cancer. 1996 , 127-146		3
198	Retinoids in clinical cancer therapy. <i>Cancer Treatment and Research</i> , 1996 , 87, 305-42	3.5	9

197	Chemoprevention in head and neck cancer. <i>Cancer Treatment and Research</i> , 2001 , 106, 221-35	3.5	8
196	Experimental therapeutic approaches for recurrent head and neck cancer. <i>Cancer Treatment and Research</i> , 1995 , 74, 263-81	3.5	3
195	Squamous differentiation and retinoids. <i>Cancer Treatment and Research</i> , 1995 , 74, 43-72	3.5	4
194	Biology and reversal of aerodigestive tract carcinogenesis. <i>Cancer Treatment and Research</i> , 1995 , 74, 89-115	3.5	4
193	Fluorouracil modulation in head and neck cancer. 1993 , 339, 197-208; discussion 219-21		4
192	Lung cancer chemoprevention. <i>Cancer Treatment and Research</i> , 1995 , 72, 43-74	3.5	4
191	Genetics of lung cancer: implications for early detection and prevention. <i>Cancer Treatment and Research</i> , 1995 , 72, 91-110	3.5	5
190	The etiology and prevention of aerodigestive tract cancers. 1992 , 320, 1-19		9
189	Culture conditions affect expression of the alpha 6 beta 4 integrin associated with aggressive behavior in head and neck cancer. 1992 , 320, 69-79		3
188	Growth factors and other targets for rational application as intervention agents. 1992 , 320, 81-8		1
187	Participant enrollment, participation, and compliance in chemoprevention trials. 1992 , 320, 111-7		9
186	Carotene and retinol efficacy trial: lung cancer chemoprevention trial in heavy cigarette smokers and asbestos-exposed workers. CARET Coinvestigators and Staff. 1992 , 320, 137-40		11
185	Chemoprevention of aerodigestive epithelial cancers. 1992 , 320, 151-61		6
184	Breast cancer chemoprevention. <i>Cancer Treatment and Research</i> , 1992 , 60, 357-67	3.5	2
183	Use of vitamins A and D in chemoprevention and therapy of cancer: control of nuclear receptor expression and function. <i>Vitamins, cancer and receptors</i> . 1995 , 375, 1-15		11
182	Vitamin A chemoprevention of lung cancer. A short-term biomarker study. 1995 , 375, 17-29		0
181	Micronutrients as Intermediate Biomarkers in Chemotherapy and Enhancement for Cancer Treatments. 2001 , 55-72		1
180	Retinoids and Interferons as Antiangiogenic Cancer Drugs. 1999 , 355-370		1

179	Selecting the Right Targets for Cancer Therapy. 2004 , 3-49		0
178	Characterization of Natural Product Chemopreventive Agents. 2005 , 3-37		23
177	Lung Cancer Chemoprevention. 2005 , 305-312		1
176	Synthetic retinoids and their usefulness in biology and medicine. 2000 , 161-196		4
175	Regional Delivery of Retinoids: A New Approach to Early Lung Cancer Intervention. 1998 , 273-283		11
174	Biomarkers as Intermediate Endpoints in Chemoprevention Trials: Biological Basis of Lung Cancer Prevention. 1998 , 305-311		1
173	Prevention of ER-negative breast cancer. <i>Recent Results in Cancer Research</i> , 2009 , 181, 121-34	1.5	23
172	Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. <i>Recent Results in Cancer Research</i> , 2011 , 188, 147-62	1.5	47
171	Chemoprevention of lung cancer: new directions. <i>Recent Results in Cancer Research</i> , 2003 , 163, 172-81; discussion 264-6	1.5	1
170	Key issues in lung cancer chemoprevention trials of new agents. <i>Recent Results in Cancer Research</i> , 2003 , 163, 182-95; discussion 264-6	1.5	4
169	Head and Neck Tumors. 2003 , 357-373		2
168	Principles of Cancer Chemotherapy. 2003 , 19-66		13
167	The Retinoids: Cancer Therapy and Prevention Mechanisms. 1999 , 301-322		17
166	Chemoprevention of head and neck and lung (pre)cancer. <i>Recent Results in Cancer Research</i> , 1999 , 151, 13-25	1.5	9
165	Chemoprevention of human cancer: a reasonable strategy?. <i>Recent Results in Cancer Research</i> , 1999 , 151, 113-21	1.5	8
164	Retinoids in the Prevention and Therapy of Solid Tumours. 1995 , 93-111		3
163	Current trends in therapeutic research. <i>Recent Results in Cancer Research</i> , 1994 , 134, 183-90	1.5	1
162	Clonal Deletion, A Novel Strategy of Cancer Control that Falls Between Cancer Chemoprevention and Cancer Chemotherapy: A Clinical Experience in Liver Cancer. 2000 , 97-103		2

161	Trial of Vitamin A Analogues for Protection. 1995 , 103-108		1
160	Future of Chemoprevention. 2017 , 169-173		1
159	Biomarkers of Pulmonary Disease. 1993 , 443-468		1
158	Retinoic Acid in Epithelial and Epidermal Differentiation. 1993 , 181-206		5
157	Biology of Head and Neck Cancer. 2010 , 1015-1029		2
156	Angiogenesis, Basic Mechanisms, and Role in Head and Neck Squamous Cell Carcinoma. 2003 , 81-100		1
155	NonSmall Cell Lung Cancer. 2012 , 805-838		3
154	Cancer Chemoprevention. 2008 , 711-720		1
153	The long terminal repeat of VL30 retrotransposons contains sequences that determine retinoic acid-induced transcription in cultured keratinocytes.. 1993 , 268, 3251-3259		10
152	The level of CRABP-I expression influences the amounts and types of all-trans-retinoic acid metabolites in F9 teratocarcinoma stem cells.. 1992 , 267, 21486-21491		165
151	Inhibition of mitogen-induced c-fos expression in melanoma cells by retinoic acid involves the serum response element.. 1992 , 267, 19971-19977		19
150	Expression of cellular retinoic acid-binding protein (type II) in Escherichia coli. Characterization and comparison to cellular retinoic acid-binding protein (type I).. 1993 , 268, 21545-21552		78
149	Cancer of the Larynx. 2006 , 627-637		11
148	Cancers of the Oral Cavity and Pharynx. 2006 , 674-696		46
147	A phase II trial of isotretinoin and alpha interferon in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. 1998 , 21, 591-4		17
146	Formation of retinoid X receptor homodimers leads to repression of T3 response: hormonal cross talk by ligand-induced squelching. <i>Molecular and Cellular Biology</i> , 1993 , 13, 7698-7707	4.8	39
145	Familial risks of squamous cell carcinoma of the head and neck: retrospective case-control study. 1996 , 313, 716-21		107
144	Molecularly targeted approaches to the chemoprevention of lung cancer. 2004 , 10, 4249s-4253s		28

143	An Integrated Approach for Preventing Oral Cavity and Oropharyngeal Cancers: Two Etiologies with Distinct and Shared Mechanisms of Carcinogenesis. 2020 , 13, 649-660		6
142	Turning back the clock: retinoic acid modifies intrinsic aging changes. 1994 , 94, 1711-2		9
141	Aetiology of head and neck cancer. 2008 , 2351-2358		1
140	Vitamin A and retinoid derivatives for lung cancer: a systematic review and meta analysis. <i>PLoS ONE</i> , 2011 , 6, e21107	3-7	43
139	Construction of a pathological risk model of occult lymph node metastases for prognostication by semi-automated image analysis of tumor budding in early-stage oral squamous cell carcinoma. 2017 , 8, 18227-18237		17
138	Anti-tumor activity of fenretinide complexed with human serum albumin in lung cancer xenograft mouse model. 2014 , 5, 4811-20		17
137	Combination of physical activity, nutrition, or other metabolic factors and vaccine response. 2007 , 12, 4997-5029		8
136	Carotenoids as Cancer Preventive Agents. 2007 , 307-332		1
135	Gene targets of sulforaphane in head and neck squamous cell carcinoma. 2019 , 20, 5335-5344		2
134	Chemoprevention of oral cancer: Green tea experience. 2014 , 5, 3-7		27
133	Second primary malignancies in laryngeal carcinoma patients treated with definitive radiotherapy. 2019 , 56, 29-34		3
132	Lung cancer. 2005 , 25, 1-12		16
131	Relationship between head and neck cancer therapy and some genetic endpoints. 2014 , 5, 93-102		14
130	Proposed role of gap junctional communication in retinoid-induced suppression of proliferation and inhibition of neoplastic transformation. 2000 , 197-208		
129	Metástase cervical de tumor primário oculto: estudo de 107 casos. 2000 , 27, 89-93		1
128	Head and Neck Cancer. 2001 , 163-176		
127	IDENTIFICATION OF EFFECTIVE RETINOIDS FOR INHIBITING GROWTH AND INDUCING APOPTOSIS IN BLADDER CANCER CELLS. 2001 , 986-992		
126	Retinoids for preventing the progression of cervical intraepithelial neoplasia.		

125 Vitamin A and Gene Expression. **2001**, 283-319

124 Epitheliale Präkanzerosen und Karzinome der Haut. **2002**, 861-893

123 Chemoprävention. **2003**, 439-445

122 Principles of Cancer Chemoprevention. **2003**, 67-77

121 Aerodigestive Tract Chemoprevention Trials and Prevention of Second Primary Tumors. **2003**, 271-285

120 Nuclear Receptor Superfamily. **2004**, 195-208

1

119 The Retinoids and Cancer Chemoprevention. **2004**, 277-288

3

118 Oral Health and Nutrition. **2004**, 533-545

117 Vitamin A, β -Carotene, and Cancer. **2005**,

116 Cancer Chemoprevention. **2006**, 1318-1340

1

115 Oncology. **2007**, 439-457

114 Complementary and Alternative Medicine. **2008**, 545-561

113 Modulation of Gene Expression by Dietary Carotenoids and Retinoids. **2008**,

112 Chemoprevention. **2009**, 267-279

111 Nutrition and Oral Health: A Two-Way Relationship. **2009**, 247-262

110 Cancer Prevention. **2009**, 351-392

109 Biological therapy of squamous cell cancers of the head and neck. **2009**, 713-721

108 Chemoprevention of Head and Neck Cancer. **2010**, 81-93

1

- 107 Chemotherapy and Targeted Biologic Agents for Head and Neck Cancer. **2010**, 1051-1063
- 106 Chemoprevention of Head and Neck Cancers. **2010**, 187-202
- 105 Chemoprevention of head and neck cancer. **2010**, 36, 452-455
- 104 Photodynamic Therapy for Laryngeal Cancers. **2010**, 2, 195-199
- 103 Chemoprevention. **2011**, 209-226
- 102 Studies on the Anticancer Effect of Apigenin in KB Cell Xenograft Nude Mouse Model. **2010**, 20, 1519-1524 2
- 101 Head and Neck Cancer Prevention. **2011**, 41-55 1
- 100 White Lesions. **2012**, 79-113
- 99 Overview. **2012**, 543-551
- 98 Larynx and Hypopharynx Cancer. **2012**, 639-663 2
- 97 Nasopharyngeal Carcinoma. **2012**, 619-638
- 96 Benign and Malignant Tumors of the Esophagus. **2013**, 579-598
- 95 Kopf-Hals-Tumoren. **2013**, 431-515
- 94 Lung Cancer Prevention. 105-114
- 93 The PI3K Signaling Pathway in Head and Neck Squamous Cell Carcinoma. **2014**, 131-161
- 92 Efficacy of Varunadi Ghritha (polyherbal compound) in treated head and neck cancer cases as a biological response modifier. **2014**, 35, 168-74 2
- 91 Free radicals as carcinogens and their quenchers as anticarcinogens. **1991**, 8, 121-40 9
- 90 Multiple primary squamous carcinomas of the upper aerodigestive tract. **1992**, 320, 27-9 3

89	Evaluation: how should a new treatment be evaluated?. 1992 , 245-257		
88	Regulation of gene expression by thyroid hormones and retinoic acid. 1992 , 14, 185-209		
87	Chemoprevention. 1992 , 73-74		
86	Multiple members of the retinoic acid receptor family are capable of mediating the granulocytic differentiation of HL-60 cells. <i>Molecular and Cellular Biology</i> , 1992 , 12, 3743-3749	4.8	16
85	Prognosis and therapy of myelodysplastic syndromes. <i>Cancer Treatment and Research</i> , 1993 , 64, 233-67	3.5	
84	New Chemotherapeutic Agents: A Selection of Some of the Most Promising New Drugs. 1993 , 335-346		
83	Multiple mechanisms: the example of vitamin A. <i>Basic Life Sciences</i> , 1993 , 61, 17-25		3
82	Retinoids and carotenoids upregulate gap-junctional communication: correlation with enhanced growth control and cancer prevention. 1993 , 301-309		1
81	The Role of Chemotherapy in Head and Neck Malignancy. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 1993 , 5, 303-317	3.4	2
80	Molecular Mechanisms of Thyroid Hormone and Retinoic acid Action. 1994 , 193-211		
79	Retinoid chemoprevention of aerodigestive carcinogenesis. 1994 , 298-302		
78	Unkonventionelle Krebstherapieverfahren unter besonderer Berücksichtigung urologischer Malignome. 1994 , 639-679		
77	Second primary tumors in oral and oropharyngeal cancer. <i>Recent Results in Cancer Research</i> , 1994 , 134, 121-32	1.5	1
76	Intensified concomitant chemoradiotherapy for poor prognosis head and neck cancer. 1994 , 283-287		
75	MANAGEMENT OF MUCOSAL PREMALIGNANT LESIONS. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 1994 , 6, 431-443	3.4	6
74	Epitheliale Präkanzerosen und Karzinome der Haut. 1995 , 797-833		
73	Kopf- und Halstumoren. 1995 , 374-403		
72	Distant metastases from head and neck squamous cancer: the role of adjuvant chemotherapy. <i>Cancer Treatment and Research</i> , 1995 , 74, 243-62	3.5	

- 71 Kehlkopf. **1996**, 389-400
- 70 Lippen und Mundhöhle. **1996**, 329-345
- 69 Turbo-Therapie zur Behandlung von Präkanzerosen. *Fortschritte Der Praktischen Dermatologie Und Venerologie*, **1997**, 277-283
- 68 Unkonventionelle Krebstherapieverfahren unter besonderer Berücksichtigung urologischer Malignome. **1997**, 741-781
- 67 Epidermal Growth Factor Receptor Expression in Head and Neck Tumorigenesis and Saturation of EGFR with Monoclonal Antibody RG83852. **1997**, 65-87
- 66 The Science of Neoplasia. **1997**, 249-255
- 65 Management of head and neck cancer. **1997**, 179-184
- 64 Medical Oncology in the Management of Head and Neck Cancers. *Oral and Maxillofacial Surgery Clinics of North America*, **1997**, 9, 433-450 3-4 1
- 63 Therapeutic manipulation of apoptosis in cancer and neurological disease. **1998**, 281-303
- 62 The effect of 13-cis-retinoic acid chemoprevention on human serum retinol levels. *Cancer Detection and Prevention*, **1998**, 22, 51-6 1
- 61 Chemoprevention of Lung Cancer. **1998**, 263-272
- 60 Kopf- und Halstumoren. **1998**, 436-475 1
- 59 Prevention and Early Detection of Lung Cancer-Clinical Aspects. **1998**, 1-14
- 58 Clinical Pharmacology of Vitamin A and Retinoids. **1998**, 31-38
- 57 The Use of Antioxidants in the Treatment of Mucocutaneous Lesions. *Oral and Maxillofacial Surgery Clinics of North America*, **1998**, 10, 45-56 3-4
- 56 Cancer Chemotherapy. **1999**, 36-118 1
- 55 A Brief Review of Cancer Chemoprevention. **1999**, 119-161
- 54 Cancer Chemoprevention. **2015**, 809-824.e4

53	Lugol Chromoscopy in the Follow-up of Head and Neck Carcinoma. <i>Annals of Maxillofacial Surgery</i> , 2017 , 7, 188-193	1
52	The PI3K Signaling Pathway in Head and Neck Squamous Cell Carcinoma. <i>Current Cancer Research</i> , 2018 , 117-154	0.2
51	Lung Cancer Prevention. 2019 , 511-542	
50	Chemoprevention in Oral Cancer. 2020 , 13-22	0
49	Chemoprevention in Oral Cancer. <i>Textbooks in Contemporary Dentistry</i> , 2020 , 227-237	0.8
48	PS4DR: A multimodal workflow for identification and prioritization of drugs based on pathway signatures.	
47	Lifestyle Interventions for the Prevention of Oral Cancer. <i>Textbooks in Contemporary Dentistry</i> , 2020 , 215-225	0.8 0
46	PS4DR: A multimodal workflow for identification and prioritization of drugs based on pathway signatures.	
45	PS4DR: A multimodal workflow for identification and prioritization of drugs based on pathway signatures.	
44	PS4DR: A multimodal workflow for identification and prioritization of drugs based on pathway signatures.	
43	RNA/DNA Based Detection of Minimal Residual Head and Neck Cancer. 2003 , 19-45	
42	Evidence-Based Cancer Prevention Research: A Multidisciplinary Perspective on Cancer Prevention Trials. 2006 , 301-316	
41	Chemoprevention of Lung Cancer. 2006 , 609-626	
40	Health services research in head and neck cancer. <i>Cancer Treatment and Research</i> , 1998 , 97, 159-75	3.5
39	RNA/DNA Based Detection of Minimal Residual Head and Neck Cancer. <i>Cancer Metastasis - Biology and Treatment</i> , 2003 , 19-45	
38	Strategies in Lung Cancer Chemoprevention. 2005 , 297-304	
37	Chemoprevention of Upper Aerodigestive Tract Cancer. 2005 , 371-382	
36	Chemoprevention in Head and Neck Cancer. 2005 , 279-303	

35 Kopf-Hals-Tumoren. **2006**, 373-450

34	Experience of a Portuguese radiation therapy department in the treatment of synchronous and metachronous head, neck, and oesophageal cancers. <i>Porto Biomedical Journal</i> , 2020 , 5, e092	1.1	
33	Hyperplasia and tumours in lung, breast and other tissues in mice carrying a RAR beta 4-like transgene. <i>EMBO Journal</i> , 1994 , 13, 5570-80	13	13
32	RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. <i>EMBO Journal</i> , 1995 , 14, 1187-97	13	47
31	Immunohistochemical analysis of retinoic acid receptor-alpha in human breast tumors: retinoic acid receptor-alpha expression correlates with proliferative activity. <i>American Journal of Pathology</i> , 1996 , 148, 1905-14	5.8	21
30	Retinoic acid induces cells cultured from oral squamous cell carcinomas to become anti-angiogenic. <i>American Journal of Pathology</i> , 1996 , 149, 247-58	5.8	53
29	Cellular localization of retinoic acid receptor-gamma expression in normal and neoplastic skin. <i>American Journal of Pathology</i> , 1992 , 140, 1463-71	5.8	19
28	Expression of cellular retinol- and cellular retinoic acid-binding proteins in the rat cervical epithelium is regulated by endocrine stimuli during normal squamous metaplasia. <i>American Journal of Pathology</i> , 1994 , 144, 148-59	5.8	9
27	Expression of serine proteinases and metalloproteinases in organ-cultured human skin. Altered levels in the presence of retinoic acid and possible relationship to retinoid-induced loss of epidermal cohesion. <i>American Journal of Pathology</i> , 1994 , 145, 561-73	5.8	11
26	The nuclear retinoid receptors. <i>International Journal of Experimental Pathology</i> , 1993 , 74, 117-26	2.8	10
25	Establishment & characterization of lymphoblastoid cell lines from patients with multiple primary neoplasms in the upper aero-digestive tract & healthy individuals. <i>Indian Journal of Medical Research</i> , 2012 , 135, 820-9	2.9	6
24	Molecular basis of differentiation therapy for soft tissue sarcomas. <i>Trends in Cancer Research</i> , 2010 , 6, 69-90	2	5
23	Decreased Expression of Retinoid X Receptors During Human and Azoxy methane-induced Colorectal Carcinogenesis in the Rat. <i>Anticancer Research</i> , 2016 , 36, 2659-64	2.3	0
22	Evaluation of the prevalence of metachronous second primary malignancies in hypopharyngeal carcinoma and their effect on outcomes.. <i>Cancer Medicine</i> , 2022 ,	4.8	1
21	A 13-Genes DNA Methylation Analysis Using Oral Brushing Specimens as an Indicator of Oral Cancer Risk: A Descriptive Case Report.. <i>Diagnostics</i> , 2022 , 12,	3.8	0
20	Secondary primary malignancy in patients with head and neck squamous cell carcinoma: 27-year experience from the perspective of diagnostic tools.. <i>PLoS ONE</i> , 2022 , 17, e0263773	3.7	0
19	A systematic review of oral retinoids for treatment of acneiform eruptions induced by epidermal growth factor receptor inhibitors.. <i>Dermatologic Therapy</i> , 2022 , e15412	2.2	0
18	Preclinical evidence for pioglitazone and bexarotene combination in oral cancer chemoprevention.. <i>Head and Neck</i> , 2021 ,	4.2	3

17	Randomized Crossover Trial Evaluating Detoxification of Tobacco Carcinogens by Broccoli Seed and Sprout Extract in Current Smokers.. <i>Cancers</i> , 2022 , 14,	6.6	
16	Retinoic Acid Analogues Inhibit Human Herpesvirus 8 Replication. <i>Antiviral Therapy</i> , 2008 , 13, 199-210	1.6	13
15	Preoperative prediction model to evaluate salvage surgery in patients with recurrent or second primary oral cavity squamous cell carcinoma. <i>Oral Oncology</i> , 2022 , 131, 105951	4.4	0
14	Circulating Endogenous Retinoic Acid Concentrations among Participants Enrolled in a Randomized Placebo-Controlled Clinical Trial of Retinyl Palmitate. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004 , 13, 1687-1692	4	6
13	Prevention of carcinogen-induced oral cancers by polymeric black tea polyphenols via modulation of EGFR-Akt-mTOR pathway. 2022 , 12,		
12	Terpenoids as Chemopreventive Agents and Their Interpretation in Animal Models and Human Clinical Trials. 2022 , 1-19		0
11	Complementary and Integrative Medicine in Head and Neck Cancer. 2022 ,		0
10	Head and neck surgical oncology. 2022 , 126, 860-864		0
9	Chemotherapy for primary cancer can reduce the risk of head and neck second primary malignancy: a propensity-matched analysis.		1
8	Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.		0
7	Terpenoids as Chemopreventive Agents and Their Interpretation in Animal Models and Human Clinical Trials. 2023 , 727-745		0
6	Segundas neoplasias esofágicas tras un tumor bñdice de cabeza y cuello: incidencia, factores de riesgo y pronñstico. 2023 ,		0
5	Recurrence in Oral Squamous Cell Carcinoma Associated with Wide Field of Cancerization: Analysis of 93 Cases.		1
4	Second primary tumor versus recurrent oral squamous cell carcinoma: Effect of inconsistent definitions on evidence synthesis. 2022 , 5, 719		0
3	Chemoprevention of oral cancer: A review and future perspectives. 2023 , 45, 1045-1059		0
2	Antioxidant and Anti-Tumor Effects of Dietary Vitamins A, C, and E. 2023 , 12, 632		0
1	Oral Squamous Cell Carcinoma and Concomitant Primary Tumors, What Do We Know? A Review of the Literature. 2023 , 30, 3721-3734		0